<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer - Ngoi, NYL - 2022 | Cochrane Library</title> <meta content="Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer - Ngoi, NYL - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012007.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer - Ngoi, NYL - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012007.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012007.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer" name="citation_title"/> <meta content="Natalie YL Ngoi" name="citation_author"/> <meta content="National University Cancer Institute" name="citation_author_institution"/> <meta content="Nicholas LX Syn" name="citation_author"/> <meta content="Robby M Goh" name="citation_author"/> <meta content="National University Cancer Institute" name="citation_author_institution"/> <meta content="Boon Cher Goh" name="citation_author"/> <meta content="National University Cancer Institute" name="citation_author_institution"/> <meta content="Ruby Yun-Ju Huang" name="citation_author"/> <meta content="National University of Singapore" name="citation_author_institution"/> <meta content="Yu Yang Soon" name="citation_author"/> <meta content="National University Cancer Institute" name="citation_author_institution"/> <meta content="Elizabeth James" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Adrian Cook" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Andrew Clamp" name="citation_author"/> <meta content="The Christie NHS Foundation Trust and University of Manchester" name="citation_author_institution"/> <meta content="David SP Tan" name="citation_author"/> <meta content="david_sp_tan@nuhs.edu.sg" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD012007.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/02/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012007.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012007.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012007.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bevacizumab [therapeutic use]; Carboplatin [adverse effects]; Carcinoma, Ovarian Epithelial [drug therapy, surgery]; *Ovarian Neoplasms [surgery]; *Paclitaxel [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012007.pub2&amp;doi=10.1002/14651858.CD012007.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WbpyPs9C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012007\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012007\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012007.pub2",title:"Weekly versus tri\\u2010weekly paclitaxel with carboplatin for first\\u2010line treatment in women with epithelial ovarian cancer",firstPublishedDate:"Feb 21, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012007.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012007.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012007.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012007.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012007.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012007.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012007.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012007.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012007.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012007.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11169 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012007.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-sec-0083"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/appendices#CD012007-sec-0099"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/table_n/CD012007StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/table_n/CD012007StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0004">Natalie YL Ngoi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0005">Nicholas LX Syn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0006">Robby M Goh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0007">Boon Cher Goh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0008">Ruby Yun-Ju Huang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0009">Yu Yang Soon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0010">Elizabeth James</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0011">Adrian Cook</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0012">Andrew Clamp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information#CD012007-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>David SP Tan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information/en#CD012007-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 February 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012007.pub2">https://doi.org/10.1002/14651858.CD012007.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012007-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012007-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012007-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012007-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012007-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD012007-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012007-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012007-abs-0001" lang="en"> <section id="CD012007-sec-0001"> <h3 class="title" id="CD012007-sec-0001">Background</h3> <p>Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases were diagnosed in 2018, with 184,799 deaths. The lack of an effective screening strategy has led to the majority of women being diagnosed at an advanced stage. For these women, intravenous carboplatin combined with paclitaxel for six cycles is widely accepted as the standard first‐line treatment for epithelial ovarian cancer, in combination with debulking surgery. However, there is conflicting evidence regarding the optimal dosing schedule of paclitaxel when combined with carboplatin in this setting. </p> </section> <section id="CD012007-sec-0002"> <h3 class="title" id="CD012007-sec-0002">Objectives</h3> <p>To compare the efficacy and tolerability of intravenous weekly paclitaxel with that of tri‐weekly paclitaxel, in combination with intravenous carboplatin, as first‐line treatment for epithelial ovarian cancer (defined as epithelial ovarian, primary peritoneal and fallopian tube cancer). </p> </section> <section id="CD012007-sec-0003"> <h3 class="title" id="CD012007-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, and Embase databases for relevant studies up to 15 November 2021, using keywords and MeSH terms. We additionally handsearched conference libraries, online clinical trial databases and screened through lists of retrieved references. </p> </section> <section id="CD012007-sec-0004"> <h3 class="title" id="CD012007-sec-0004">Selection criteria</h3> <p>We Included randomised controlled trials (RCTs) comparing weekly paclitaxel in combination with carboplatin versus tri‐weekly paclitaxel in combination with carboplatin, for treatment of newly‐diagnosed epithelial ovarian cancer. </p> </section> <section id="CD012007-sec-0005"> <h3 class="title" id="CD012007-sec-0005">Data collection and analysis</h3> <p>We used the hazard ratio (HR) to estimate the primary efficacy outcomes progression‐free (PFS) and overall survival (OS). We used the risk ratio (RR) to estimate the primary toxicity outcome of severe neutropenia and secondary outcomes of quality of life (QoL) and treatment‐related adverse events. Two review authors independently selected studies, extracted data, and assessed risk of bias, using standard Cochrane methodological procedures. We included individual participant data (IPD) from one of the included studies, ICON‐8, provided by the study team. We analysed data using a random‐effects model in Review Manager 5.4 software. Additionally, we reconstructed IPD for PFS and OS data from published Kaplan‐Meier curves from all studies and subsequently pooled these to analyse the two primary efficacy outcomes. </p> </section> <section id="CD012007-sec-0006"> <h3 class="title" id="CD012007-sec-0006">Main results</h3> <p>From 2469 records, we identified four eligible RCTs with data for 3699 participants. All eligible studies were included in the main meta‐analysis and reported on PFS and OS. </p> <p>There was likely a slight improvement in PFS when paclitaxel was dosed weekly compared to tri‐weekly (HR 0.89, 95% confidence interval (CI) 0.81 to 0.98; 4 studies, 3699 participants; moderate‐certainty evidence). We found little to no improvement in OS when paclitaxel was dosed weekly compared to tri‐weekly (HR 0.92, 95% CI 0.79 to 1.06; 4 studies, 3699 participants; high‐certainty evidence). There was likely little to no difference in high‐grade (grade 3 or 4) neutropenia when paclitaxel was dosed weekly compared to tri‐weekly (RR 1.11, 95% CI 0.86 to 1.43; 4 studies, 3639 participants; moderate‐certainty evidence). However, weekly paclitaxel increased high‐grade (grade 3 or 4) anaemia when compared to tri‐weekly dosing (RR 1.57, 95% CI 1.12 to 2.20; 4 studies, 3639 participants; high‐certainty evidence). There may be little to no difference in high‐grade neuropathy when paclitaxel was dosed weekly compared to tri‐weekly (RR 1.12, 95% CI 0.64 to 1.94; 4 studies, 3639 participants; low‐certainty evidence). The overall risk of detection bias and performance bias was low for OS, but was unclear for other outcomes, as treatments were not blinded. The risk of bias in other domains was low or unclear. </p> <p>We note that OS data were immature for three of the included studies (GOG‐0262, ICON‐8 and MITO‐7). </p> </section> <section id="CD012007-sec-0007"> <h3 class="title" id="CD012007-sec-0007">Authors' conclusions</h3> <p>Weekly paclitaxel combined with carboplatin for first‐line treatment of epithelial ovarian cancer likely improves PFS slightly (moderate‐certainty evidence) but not OS (high‐certainty evidence), compared to tri‐weekly paclitaxel combined with carboplatin. However, this was associated with increased risk for high‐grade anaemia, treatment discontinuation, dose delays and dose omissions (high‐ to low‐certainty evidence). Our findings may not apply to women receiving bevacizumab in first‐line therapy, those receiving treatment in the neo‐adjuvant setting, or those with rare subtypes of clear cell or mucinous ovarian cancer. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012007-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012007-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012007-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012007-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012007-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012007-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012007-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012007-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD012007-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012007-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012007-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012007-abs-0002" lang="en"> <h3>Does weekly dosing of paclitaxel improve survival, compared with tri‐weekly dosing of paclitaxel in the initial treatment of ovarian cancer? </h3> <p><b>Background</b><br/>Ovarian cancer is the sixth most common cancer worldwide. Treatment consists of a combination of surgery and chemotherapy (most commonly including paclitaxel and carboplatin), with the aim to reduce or delay the return of the cancer (known as progression‐free survival (PFS)), and improve chances for cancer survival (known as overall survival (OS)). Several clinical trials (studies) have investigated whether the dosing schedule (timing) of paclitaxel affects these outcomes. However, the results from reported studies are conflicting. </p> <p><b>The aim of the review</b><br/>We reviewed the evidence about the effect of different schedules of paclitaxel on survival in women with newly‐diagnosed ovarian cancer. </p> <p><b>Study characteristics</b><br/>The evidence is current up to 15 November 2021. We included four studies with a total of 3699 participants. All studies included were randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) of women aged 18 years or older with newly diagnosed ovarian cancer. The studies compared weekly versus tri‐weekly dosing of paclitaxel, plus carboplatin. </p> <p><b>Main findings</b><br/>We found that, compared with tri‐weekly paclitaxel dosing, weekly paclitaxel plus carboplatin likely slightly improves progression‐free survival, although results in little to no difference in overall survival (high‐certainty evidence). </p> <p>For adverse effects, we found that weekly paclitaxel plus carboplatin likely results in little to no difference in severe low neutrophil count (a type of white blood cell that helps to fight infections) (moderate‐certainty evidence); increases severe anaemia (haemoglobin level ‐ an important component of red blood cells) (high‐certainty evidence) and may result in little to no difference in severe damage to nerves (low‐certainty evidence). </p> <p><b>Conclusions</b><br/>Weekly dosing of paclitaxel likely prolongs progression‐free survival compared to tri‐weekly dosing of paclitaxel, when combined with carboplatin in the initial treatment of ovarian cancer. However, this does not improve overall survival. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012007-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012007-sec-0094"></div> <h3 class="title" id="CD012007-sec-0095">Implications for practice</h3> <section id="CD012007-sec-0095"> <p>The results of this meta‐analysis are based on four studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>), which included 3699 women with ovarian cancer. It provides moderate‐certainty evidence that weekly paclitaxel combined with carboplatin slightly improves progression‐free survival (PFS) compared to tri‐weekly paclitaxel combined with carboplatin in women receiving first‐line treatment for ovarian cancer. However, high‐certainty evidence also suggests that weekly paclitaxel with carboplatin leads to little or no improvement in overall survival compared to standard tri‐weekly dosing. In addition, high‐certainty evidence suggest that women receiving weekly paclitaxel combined with carboplatin suffered increase risk for severe anaemia. There was also increased risk for treatment discontinuation, dose delays and dose omissions observed on subgroup analysis. Moderate‐ and low‐certainty evidence, respectively, suggest no increased risk for severe neutropenia or severe neuropathy with this approach. </p> </section> <h3 class="title" id="CD012007-sec-0096">Implications for research</h3> <section id="CD012007-sec-0096"> <p>Evolving treatment paradigms in the first‐line treatment of ovarian cancer, specifically in advanced stage disease, have led to the introduction of maintenance poly‐ADP ribose polymerase inhibitors (PARPi) after the completion of first‐line tri‐weekly carboplatin and paclitaxel, based on improvements in PFS on randomised studies (<a href="./references#CD012007-bbs2-0030" title="Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402.">Gonzalez‐Martin 2019</a>). It remains unclear if the introduction of additional agents, such as bevacizumab or PARPi maintenance therapy after first‐line chemotherapy, will dilute any potential PFS benefits retrieved from increasing paclitaxel dose‐intensity during chemotherapy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012007-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012007-sec-0008"></div> <div class="table" id="CD012007-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Weekly paclitaxel plus carboplatin compared to Three‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> first‐line treatment of ovarian cancer<br/><b>Setting:</b> Hospital<br/><b>Intervention:</b> Weekly paclitaxel plus carboplatin<br/><b>Comparison:</b> Three‐weekly paclitaxel plus carboplatin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tri‐weekly paclitaxel plus carboplatin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Weekly paclitaxel plus carboplatin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.89<br/>(0.81 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3699<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin likely improves progression‐free survival slightly.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/>(146 to 173) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>follow‐up: range 22.3 months to 76.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.92<br/>(0.79 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3699<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin results in little to no difference in overall survival.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/>(53 to 71) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological adverse event: Grade 3/4 neutropenia<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.86 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3639<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin likely results in little to no difference in Grade 3/4 neutropenia. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>534 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000<br/>(459 to 764) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological adverse event: Grade 3/4 anaemia<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.57<br/>(1.12 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3639<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin increases Grade 3/4 anaemia .</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<br/>(177 to 349) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.64 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3639<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin may result in little to no difference in Grade 3/4 neuropathy. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/>(26 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias (detection bias as patients and investigators were not blinded). </p> <p><sup>2</sup> Downgraded one level for severe statistical heterogeneity. </p> <p><sup>3</sup> Downgraded one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012007-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012007-sec-0009"></div> <p>After surgery to remove the ovarian cancer, carboplatin and paclitaxel chemotherapy dosed every three weeks (tri‐weekly) for six cycles is widely‐accepted as standard first‐line treatment for epithelial ovarian cancer. However, it is unclear if different dosing schedules for paclitaxel lead to differences in treatment effectiveness in prolonging time to cancer progression or death. </p> <section id="CD012007-sec-0010"> <h3 class="title" id="CD012007-sec-0010">Description of the condition</h3> <p>Epithelial ovarian cancer is the sixth most common cancer worldwide: 295,414 new cases were diagnosed in 2018, with 184,799 deaths (<a href="./references#CD012007-bbs2-0014" title="BrayF , FerlayJ , SoerjomataramI , SiegelRL , TorreLA , JemalA .Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2018;68(6):394-424.">Bray 2018</a>). The lack of an effective screening strategy and the natural history of the disease contribute to the majority of women being diagnosed at an advanced stage. Epithelial ovarian, primary peritoneal and fallopian tube cancers are classified as a single disease entity due to their shared origin, similar natural history and similar prognosis (<a href="./references#CD012007-bbs2-0041" title="Labidi-GalySI , PappE , HallbergD , NiknafsN , AdleffV , NoeM , et al.High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications2017;8(1):1093.">Labidi‐Galy 2017</a>). In combination with surgical removal of as much visible cancer as possible, intravenous carboplatin (area under curve (AUC) 5 mg/mL to 6 mg/mL) and paclitaxel (175 mg/m<sup>2</sup> to 180 mg/m<sup>2</sup>) chemotherapy dosed tri‐weekly remains the most widely‐adopted approach to first‐line therapy for advanced ovarian cancer, and results in a high rate of initial complete response. However, approximately 75% of women eventually relapse within the first two years of diagnosis, leading to only around 30% of women achieving long‐term survival (<a href="./references#CD012007-bbs2-0017" title="BukowskiRM , OzolsRF , MarkmanM .The management of recurrent ovarian cancer. Seminars in Oncology2007;34(2 Suppl 2):S1-15.">Bukowski 2007</a>; <a href="./references#CD012007-bbs2-0039" title="JemalA , SiegelR , WardE , HaoY , XuJ , MurrayT , et al.Cancer Statistics. CA: a Cancer Journal for Clinicians2008;58(2):71-96.">Jemal 2008</a>). Recent studies have investigated the addition of intra‐peritoneal paclitaxel and cisplatin, hyperthermic intraperitoneal chemotherapy (HIPEC) (<a href="./references#CD012007-bbs2-0067" title="vanDrielWJ , KooleSN , SikorskaK , Schagen van LeeuwenJH , SchreuderHW , HermansRH , et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New England Journal of Medicine2018;378(3):230-40.">van Driel 2018</a>), as well as novel systemic therapies such as bevacizumab (<a href="./references#CD012007-bbs2-0065" title="TewariKS , BurgerRA , EnserroD , NorquistBM , SwisherEM , BradyMF , et al.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. Journal of Clinical Oncology2019;37(26):2317-28.">Tewari 2019</a>) or poly‐ADP ribose polymerase inhibitors (PARPi), or both (<a href="./references#CD012007-bbs2-0030" title="Gonzalez-MartinA , PothuriB , VergoteI , DePont ChristensenR , GraybillW , MirzaMR , et al.Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2019;381(25):2391-402.">Gonzalez‐Martin 2019</a>; <a href="./references#CD012007-bbs2-0046" title="MooreK , ColomboN , ScambiaG , KimBG , OakninA , FriedlanderM , et al.Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine2018;379(26):2495-505.">Moore 2018</a>) for the treatment of advanced ovarian cancer, with encouraging results. </p> </section> <section id="CD012007-sec-0011"> <h3 class="title" id="CD012007-sec-0011">Description of the intervention</h3> <p>Intravenous carboplatin and paclitaxel, dosed tri‐weekly, remains the widely‐accepted standard first‐line chemotherapeutic approach for women with epithelial ovarian cancer (<a href="./references#CD012007-bbs2-0010" title="BairdRD , TanDS , KayeSB .Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nature Reviews. Clinical Oncology2010;7(10):575-82.">Baird 2010</a>). The National Comprehensive Cancer Network has classified carboplatin plus paclitaxel tri‐weekly, or carboplatin plus paclitaxel tri‐weekly with bevacizumab, as preferred regimens. Other recommended regimens include carboplatin plus paclitaxel weekly, paclitaxel weekly with carboplatin tri‐weekly, carboplatin plus docetaxel and carboplatin plus liposomal doxorubicin (<a href="./references#CD012007-bbs2-0048" title="National Comprehensive Cancer Network.Ovarian cancer including fallopian tube cancer and primary peritoneal cancer Version 1; 26 February 2021. Available at www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.">National Comprehensive Cancer Network 2021</a>). Similarly, the Gynecologic Cancer InterGroup (GCIG) epithelial ovarian cancer consensus conference statement has listed acceptable front‐line regimens to be carboplatin plus paclitaxel tri‐weekly, paclitaxel weekly with carboplatin tri‐weekly, intraperitoneal cisplatin plus paclitaxel, or carboplatin plus paclitaxel tri‐weekly with bevacizumab (<a href="./references#CD012007-bbs2-0040" title="KaramA , LedermannJA , KimJW , SehouliJ , LuK , GourleyC , et al.Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Annals of Oncology2017;28(4):711-7.">Karam 2017</a>). </p> </section> <section id="CD012007-sec-0012"> <h3 class="title" id="CD012007-sec-0012">How the intervention might work</h3> <p>The basis for weekly paclitaxel chemotherapy as a dose‐intensification measure arose from the Norton‐Simon Regression Hypothesis (<a href="./references#CD012007-bbs2-0058" title="SimonR , NortonL .The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nature Clinical Practice. Oncology2006;3(8):406-7.">Simon 2006</a>). Based on this theory, the rate of tumour regrowth between treatments is proportional to the rate of tumour growth. Administering the same or higher cumulative drug dose over a shorter period of time may potentate tumour‐cell kill by minimising the opportunity for tumour regrowth between cycles of chemotherapy. Furthermore, paclitaxel has also been described to have an anti‐angiogenic effect when administered weekly (<a href="./references#CD012007-bbs2-0016" title="BrowderT , FolkmanJ , Pirie-ShepherdS .The hemostatic system as a regulator of angiogenesis. Journal of Biological Chemistry2000;275(3):1521-4.">Browder 2000</a>), given that endothelial cell proliferation and migration recovers within four days of chemotherapy administration, and more frequent dosing of chemotherapy is required to sustain angiogenesis inhibition (<a href="./references#CD012007-bbs2-0016" title="BrowderT , FolkmanJ , Pirie-ShepherdS .The hemostatic system as a regulator of angiogenesis. Journal of Biological Chemistry2000;275(3):1521-4.">Browder 2000</a>). Finally, weekly dosing of chemotherapy is potentially less myelosuppressive and may be better tolerated by people with cancer. </p> <p>Accordingly, weekly dosing of paclitaxel or carboplatin, or both has been shown to be effective and well‐tolerated in other cancer types, such as breast cancer (<a href="./references#CD012007-bbs2-0061" title="SparanoJA , ZhaoF , MartinoS , LigibelJA , PerezEA , SaphnerT , et al.Long-term follow-up of the E1199 Phase III trial evaluating the role of taxane and schedule in operable breast cancer. Journal of Clinical Oncology2015;33(21):2353-60.">Sparano 2015</a>) and non‐small cell lung cancer (<a href="./references#CD012007-bbs2-0053" title="RamalingamS , BarstisJ , PerryMC , La RoccaRV , NattamSR , RinaldiD , et al.Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. Journal of Thoracic Oncology2006;1(3):240-4.">Ramalingam 2006</a>), and has been successfully incorporated into treatment paradigms in these cancers. In breast cancer, dose‐dense adjuvant therapy for both anthracyclines and taxanes has been shown to be superior to chemotherapy dosed at tri‐weekly intervals, in terms of progression‐free survival (PFS) and overall survival (OS) (<a href="./references#CD012007-bbs2-0018" title="CitronML , BerryDA , CirrincioneC , HudisC , WinerEP , GradisharWJ , et al.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Oncology2003;21(8):1431-9.">Citron 2003</a>). Weekly paclitaxel has also been repeatedly shown to confer survival benefit over tri‐weekly paclitaxel dosing in both the adjuvant and metastatic settings in breast cancer treatment (<a href="./references#CD012007-bbs2-0061" title="SparanoJA , ZhaoF , MartinoS , LigibelJA , PerezEA , SaphnerT , et al.Long-term follow-up of the E1199 Phase III trial evaluating the role of taxane and schedule in operable breast cancer. Journal of Clinical Oncology2015;33(21):2353-60.">Sparano 2015</a>). </p> </section> <section id="CD012007-sec-0013"> <h3 class="title" id="CD012007-sec-0013">Why it is important to do this review</h3> <p>The first randomised phase III trial to demonstrate a survival benefit from weekly paclitaxel in epithelial ovarian cancer was <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>, which found that weekly paclitaxel, dosed at 80 mg/m<sup>2</sup>,was associated with improvements in PFS and OS when compared to tri‐weekly paclitaxel, dosed at 175 mg/m<sup>2</sup>, even at long‐term follow‐up. However, three other randomised phase III trials have failed to confirm this benefit in the intention‐to‐treat population (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). </p> <p>Aside from efficacy outcomes, dose‐dense and tri‐weekly carboplatin and paclitaxel therapy have other potential differences in terms of described toxicity, effect on quality of life (QoL) and cost‐effectiveness (<a href="./references#CD012007-bbs2-0042" title="LeeMX , TanDS .Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?J Gynecol Oncol2018;29(6):e96.">Lee 2018</a>). Acknowledging the limitations of direct cross‐trial comparison, toxicity outcomes appeared to differ between trials. In <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>, dose‐dense weekly paclitaxel 80 mg/m<sup>2</sup> was associated with an increase in premature therapy discontinuation compared to control and an increased incidence of treatment delays. Yet, chemotherapy completion rates on the weekly chemotherapy arms of <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> and <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> were higher compared to control. High grade anaemia was more frequent in women receiving weekly paclitaxel in both the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> and <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> studies, compared to respective controls, but was markedly lower in the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study, which recruited a predominantly white European population. In the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study, weekly paclitaxel was associated with higher rates of grade 2 or higher sensory neuropathy compared to control, whereas no differences were observed between groups in the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> and <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> studies compared to respective control. </p> <p>In light of differing conclusions amongst these studies, and the potential benefits of weekly paclitaxel therapy, further research is warranted to clarify the role of weekly paclitaxel, in combination with carboplatin, for epithelial ovarian cancer treatment. A systematic review of individualised participant data is important to determine the treatment effect of weekly paclitaxel dosing in combination with carboplatin compared to standard therapy for first‐line epithelial ovarian cancer treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012007-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012007-sec-0014"></div> <p>To compare the efficacy and tolerability of intravenous weekly paclitaxel with that of tri‐weekly paclitaxel, in combination with intravenous carboplatin, as first‐line treatment for epithelial ovarian cancer (defined as epithelial ovarian, primary peritoneal and fallopian tube cancer). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012007-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012007-sec-0015"></div> <section id="CD012007-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012007-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered only randomised controlled trials (RCTs) as studies in this review and meta‐analysis. </p> </section> <section id="CD012007-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies of adult women, 18 years or older, with newly diagnosed epithelial ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) Stage I to IV. </p> </section> <section id="CD012007-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The intervention was carboplatin, area under curve (AUC) to a total dose of 5 mg/mL/min to 6 mg/mL/min per cycle, combined with weekly paclitaxel, including metronomic (similar cumulative dosage) or dose‐dense (increased cumulative dosage) paclitaxel. We defined the control therapy as carboplatin AUC 5 mg/mL to 6 mg/mL, combined with paclitaxel 175 mg/m<sup>2</sup> to 180 mg/m<sup>2</sup>, dosed every three weeks. Other chemotherapeutic agents, including cisplatin, molecular therapies (such as those which target the epidermal growth factor receptor) and immunotherapy were allowed, but must have been given in both intervention and control groups. </p> </section> <section id="CD012007-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012007-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>Primary efficacy outcomes of interest were progression‐free survival (PFS) and overall survival (OS). </p> <p> <ul id="CD012007-list-0001"> <li> <p>PFS, defined as time from randomisation to disease progression or death from any cause.</p> </li> <li> <p>OS, defined as time from randomisation to death from any cause.</p> </li> <li> <p>The primary toxicity outcome of interest was the risk of severe neutropenia, defined as grade 3 or 4 neutropenia classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 2.0, 3.0 and 4.0 (<a href="./references#CD012007-bbs2-0019" title="National Cancer Institute (NCI).Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (publication # 09-7473) (accessed 30 August 2021).">CTCAE 2018</a>). </p> </li> </ul> </p> </section> <section id="CD012007-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012007-list-0002"> <li> <p>Adverse events, classified according to CTCAE version 2.0, 3.0 and 4.0. We extracted and grouped grades of toxicity as: </p> </li> </ul> </p> <p> <ul class="plain" id="CD012007-list-0003"> <li> <ul id="CD012007-list-0004"> <li> <p>haematological: anaemia, thrombocytopenia, leucopenia, haemorrhage;</p> </li> <li> <p>cardiac: bradycardia, atrial fibrillation;</p> </li> <li> <p>neurological: peripheral and central;</p> </li> <li> <p>skin: nail disorders, alopecia, stomatitis, mucositis, allergy;</p> </li> <li> <p>gastrointestinal: diarrhoea, anorexia, nausea, vomiting, liver dysfunction, proctitis.</p> </li> </ul> </li> </ul> </p> <p> <ul id="CD012007-list-0005"> <li> <p>Quality of life (QoL), measured using a scale that has been validated through reporting of norms in a peer‐reviewed publication, such as the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire ‐ Ovarian 28 (EORTC‐OV28) or the Functional Assessment of Cancer ‐ Ovarian (FACT‐O) questionnaire. </p> </li> </ul> </p> </section> </section> </section> <section id="CD012007-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We adapted the search strategy from the <i>Cochrane Handbook for Systemic Reviews of Interventions</i> (<a href="./references#CD012007-bbs2-0043" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al.Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Lefebvre 2021</a>). We did not apply any language or date restrictions, and considered both full‐text and abstract publications. </p> <section id="CD012007-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases.</p> <p> <ul id="CD012007-list-0006"> <li> <p>The Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group’s Trial Register (searched 15 November 2021) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 11) in the Cochrane Library (searched 15 November 2021) </p> </li> <li> <p>MEDLINE Ovid (1946 to 15 November 2021)</p> </li> <li> <p>Embase (1980 to week 45, 2021)</p> </li> </ul> </p> <p>The CENTRAL, MEDLINE and Embase search strategies are presented in <a href="./appendices#CD012007-sec-0100">Appendix 1</a><a href="./appendices#CD012007-sec-0101">Appendix 2</a>, and <a href="./appendices#CD012007-sec-0102">Appendix 3</a>, respectively. </p> </section> <section id="CD012007-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We identified all relevant articles on PubMed and carried out a further search for newly published articles using the ‘related articles’ feature. We searched references of retrieved articles for relevant articles. </p> <p>To identify ongoing trials, we searched trials registries at: <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> and <a href="http://www.cancer.gov/clinicaltrials" target="_blank">www.cancer.gov/clinicaltrials</a>. If searches identified ongoing trials without published data, we planned to contact the principal investigators to request the relevant data. We handsearched the citation lists of included studies, key textbooks and previous systematic reviews to identify further reports of trials. We also performed a handsearch of the reports of conferences in the following sources: Gynecologic Oncology (Annual Meeting of the American Society of Gynaecologic Oncologists), International Journal of Gynaecologic Cancer (Annual Meeting of the International Gynaecologic Cancer Society), Annual Meeting of European Society of Medical Oncology (ESMO), Annual Meeting of the American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO). </p> </section> </section> <section id="CD012007-sec-0026"> <h3 class="title" id="CD012007-sec-0026">Data collection and analysis</h3> <section id="CD012007-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching into a reference management database and removed any duplicates (<a href="https://www.mendeley.com/" target="_blank">www.mendeley.com/</a>). Two review authors (NLS, RMG) independently examined the remaining references and excluded any studies which did not meet the inclusion criteria. We obtained full‐text copies of potentially relevant references. Two review authors (NLS, NYN) independently assessed the eligibility of the retrieved papers and resolved any disagreements through discussion, consulting a third review author (DST) if necessary. During the course of screening the literature, we documented the overall number of studies identified, as well as the excluded studies and reasons for exclusion. Where available directly from the trial study team, we obtained individual participant data (IPD). </p> </section> <section id="CD012007-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We used the full‐text versions of the identified eligible studies to retrieve the data for analysis. The study team from one study provided IPD directly to the review authors (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>). We performed data extraction according to the guidelines proposed by Cochrane (<a href="./references#CD012007-bbs2-0044" title="LiT , HigginsJP , DeeksJJ , editor(s).Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Li 2021</a>).Two review authors (NLS, RMG) independently extracted study characteristics and outcome data from included studies onto a pre‐piloted data collection form. A second review author (NYN) double‐checked that the data were entered correctly by comparing the data presented with the study reports. The extracted data included the following information. </p> <p> <ul id="CD012007-list-0007"> <li> <p>Author, year of publication and journal citation (including language)</p> </li> <li> <p>Country</p> </li> <li> <p>Setting</p> </li> <li> <p>Inclusion and exclusion criteria</p> </li> <li> <p>Study design, methodology</p> </li> <li> <p>Study population</p> <ul id="CD012007-list-0008"> <li> <p>Total number enrolled</p> </li> <li> <p>Participant characteristics, including ethnicity</p> </li> <li> <p>Age</p> </li> <li> <p>Comorbidities</p> </li> <li> <p>Other baseline characteristics, e.g. stage, grade, histotype</p> </li> </ul> </li> <li> <p>Intervention details</p> <ul id="CD012007-list-0009"> <li> <p>Choice, dose intensity and frequency of platinum agent</p> </li> <li> <p>Dose and frequency of paclitaxel</p> </li> <li> <p>Route of paclitaxel administration</p> </li> <li> <p>Details of radiotherapy and debulking surgery if applicable</p> </li> <li> <p>Details of targeted therapy if applicable</p> </li> </ul> </li> <li> <p>Risk of bias in study</p> </li> <li> <p>Duration of follow‐up</p> </li> <li> <p>Outcomes: for each outcome, we extracted the outcome definition and unit of measurement (if relevant). </p> </li> <li> <p>Results: we extracted the number of participants allocated to each intervention group, the total number analysed for each outcome, and the number of missing participants. We collected the following types of data. </p> <ul id="CD012007-list-0010"> <li> <p>For time‐to‐event data (survival and disease progression), we extracted the log of the hazard ratio (log (HR)) and its standard error from trial reports. If these were not reported, we attempted to estimate the log (HR) and its standard error using the methods of <a href="./references#CD012007-bbs2-0052" title="ParmarMK , TorriV , StewartL .Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>. </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events), we extracted the number of women in each treatment arm who experienced the outcome of interest and the number of women assessed at endpoint, in order to estimate a risk ratio. </p> </li> <li> <p>For continuous outcomes, we extracted the final value and standard deviation of the outcome of interest and the number of women assessed at endpoint in each treatment arm at the end of follow‐up, in order to estimate the mean difference between treatment arms and its standard error. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD012007-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included studies using the Cochrane risk of bias tool, which assesses the explicit reporting of the following individual elements for RCTs (<a href="./references#CD012007-bbs2-0036" title="HigginsJP , AltmanDG , SterneJA , editor(s).Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>). </p> <p> <ul id="CD012007-list-0011"> <li> <p>Selection bias: random sequence generation and allocation concealment</p> </li> <li> <p>Performance bias: blinding of participants and personnel (women and treatment providers)</p> </li> <li> <p>Detection bias: blinding of outcome assessment</p> </li> <li> <p>Attrition bias: incomplete outcome data</p> </li> <li> <p>Reporting bias: selective reporting of outcomes</p> </li> </ul> </p> <p>Two review authors (NLS, RMG) applied the risk of bias tool independently and resolved any differences by discussion or by appeal to a third review author (NYN). We judged each item to be at high, low or unclear risk of bias, as set out in the criteria provided by <a href="./references#CD012007-bbs2-0036" title="HigginsJP , AltmanDG , SterneJA , editor(s).Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011</a>, and provided a quote from the study report or a statement, or both, as justification for the judgement for each item in the risk of bias table. These results are summarised in both a risk of bias graph and a risk of bias summary diagram. When interpreting treatment effects and meta‐analyses, we took into account the risk of bias for the studies that contributed to that outcome. Please see <a href="./appendices#CD012007-sec-0103">Appendix 4</a> for the full risk of bias criteria. </p> </section> <section id="CD012007-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For time‐to‐event data, we described the treatment effect using a hazard ratio (HR) with corresponding 95% confidence intervals (CI). For each study, we used IPD if available from the study team. If IPD were not available, we extracted information about time‐to‐event outcomes using the methods described by <a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a>. </p> <p>For dichotomous outcomes, we analysed data based on the number of events and the number of women assessed in the intervention and comparison groups, which we then used to calculate the risk ratio (RR) and corresponding 95% CI. </p> <p>For continuous outcomes, we analysed data based on the mean, standard deviation (SD) and number of women assessed for both the intervention and comparison groups to calculate mean difference (MD) between treatment arms with a 95% CI. If a trial reported the MD without giving the data for each group separately, we used this to report the study results. If more than one study measured the same outcome using different tools, we calculated the standardised mean difference (SMD) and 95% CI using the inverse variance method in RevMan 5 (<a href="./references#CD012007-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan).Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD012007-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant. For studies that had multiple treatment groups, we divided the ‘shared’ comparison group into the number of treatment groups and treated the split comparison group as independent comparisons. </p> </section> <section id="CD012007-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We dealt with missing data as suggested in the Chapter 10.12, Cochrane Handbook for Systematic Reviews <i>(</i><a href="./references#CD012007-bbs2-0037" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors).Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook..">Higgins 2021</a>), whereby we contacted study authors to obtain missing data (participant, outcome, or summary data). We did not impute any missing outcome data for any of the outcomes. We reported on the levels of loss to follow‐up and assessed this as a source of potential bias. The potential impact of missing data on the conclusions of this review are discussed. </p> </section> <section id="CD012007-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the degree of heterogeneity between studies. Where we considered studies to be similar enough (in terms of participants, settings, intervention and outcome measures) to allow pooling of data using meta‐analysis, we assessed the degree of heterogeneity by visual inspection of forest plots, by estimation of the percentage heterogeneity between studies which cannot be ascribed to sampling variation (I² statistic) (<a href="./references#CD012007-bbs2-0035" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG .Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>), by a formal statistical test of the significance of the heterogeneity (Chi²) (<a href="./references#CD012007-bbs2-0022" title="DeeksJJ , AltmanDG , BradburnMJ .Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM , Davey SmithG , AltmanDG , editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. London, UK: BMJ Publishing Group, 2001.">Deeks 2001</a>) and, where possible, by subgroup analyses. When using the I² statistic to quantify possible heterogeneity, substantial heterogeneity was detected by I² &gt; 50%. A low P value (P &lt; 0.10) in the Chi² test indicated heterogeneity. If there was evidence of substantial clinical, methodological or statistical heterogeneity across included studies we did not report pooled results from meta‐analysis but instead used a narrative approach to data synthesis. We considered pooling results through meta‐analysis even when there was substantial heterogeneity, if the direction of effect appeared to be consistent across studies. </p> </section> <section id="CD012007-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In a meta‐analysis of more than 10 studies, funnel plots corresponding to the primary outcome would be examined to assess the potential for small study effects such as publication bias. Funnel plot asymmetry would be assessed visually, and exploratory analyses would be performed to investigate any asymmetry found (<a href="./references#CD012007-bbs2-0063" title="SterneJA , EggerM , MoherD , editor(s).Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Sterne 2011</a>). As our review only included four studies, this was not possible. </p> </section> <section id="CD012007-sec-0035"> <h4 class="title">Data synthesis</h4> <p>As sources of variation are likely between studies, we pooled the study results using the random‐effects model in <a href="./references#CD012007-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan).Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>, with inverse variance for meta‐analysis (<a href="./references#CD012007-bbs2-0024" title="DerSimonianR , LairdN .Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). For time‐to‐event data, we pooled hazard ratios using the generic inverse variance facility of <a href="./references#CD012007-bbs2-0054" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan).Version 5.4.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>. </p> <p>For dichotomous outcomes, we calculated the RRs as appropriate for each study then pooled them. For continuous outcomes, we pooled the MDs between the treatment arms at the end of follow‐up when all studies measured the outcome on the same scale; otherwise we pooled the SMDs. </p> <p>We only undertook meta‐analyses when we felt them to be meaningful, that is, if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. We planned to report any skewed data as medians and interquartile ranges. </p> </section> <section id="CD012007-sec-0036"> <h4 class="title">Reconstruction and synthesis of individual participant data</h4> <p>We reconstructed participant‐level survival data from published Kaplan‐Meier curves using validated algorithms by Guyot and colleagues (<a href="./references#CD012007-bbs2-0027" title="FreemanSC , SuttonAJ , CooperNJ .Uptake of methodological advances for synthesis of continuous and time-to-event outcomes would maximize use of the evidence base. Journal of Clinical Epidemiology2020;124:94-105. [PMID: 32407766]">Freeman 2020</a>; <a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a>; <a href="./references#CD012007-bbs2-0051" title="PapadimitropoulouK , StijnenT , RileyRD , DekkersOM , le CessieS .Meta-analysis of continuous outcomes: using pseudo IPD created from aggregate data to adjust for baseline imbalance and assess treatment-by-baseline modification. Research Synthesis Methods2020;11(6):780-94. [PMID: 32643264]">Papadimitropoulou 2020</a>; <a href="./references#CD012007-bbs2-0060" title="SongY , SunF , RedlineS , WangR .Random-effects meta-analysis of combined outcomes based on reconstructions of individual patient data. Research Synthesis Methods2020;11(5):594-616. [PMID: 32270909]">Song 2020</a>; <a href="./references#CD012007-bbs2-0064" title="SynNL , KabirT , KohYX , TanHL , WangLZ , ChinBZ , et al.Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies. Annals of Surgery2020;272(2):253-65. [PMID: 32675538]">Syn 2020</a>; <a href="./references#CD012007-bbs2-0068" title="WeiY , RoystonP .Reconstructing time-to-event data from published Kaplan-Meier curves. The Stata Journal2017;17(4):786-802. [PMID: 29398980]">Wei 2017</a>). However, we did not have to reconstruct the data from the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study because the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> investigators provided the original participant‐level survival time. Briefly, we downloaded, preprocessed, and digitised raster images of survivor curves to obtain their step function, including the timings of the steps (<a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a>). We used additional information such as number‐at‐risk tables and total number of events, when reported, to further improve the calibration of the reconstruction algorithm (<a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a>). We then recovered time‐to‐event information on individual women by solving the inverted Kaplan‐Meier product‐limit equations (<a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a>). Side‐by‐side comparisons of reconstructed and original curves demonstrated that the algorithms robustly recovered participant‐level survival time from published studies. </p> <p>We analysed time‐to‐event endpoints of PFS and OS using both the one‐stage method of <a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a> (i.e. using reconstructed or original individual participant data, as shown in the Kaplan Meier plots in <a href="#CD012007-fig-0001">Figure 1</a> and <a href="#CD012007-fig-0002">Figure 2</a>), and a two‐stage approach (i.e. the prespecified inverse variance‐weighted meta‐analyses, as shown in the forest plots (<a href="./references#CD012007-fig-0006" title="">Analysis 1.1</a> and <a href="./references#CD012007-fig-0014" title="">Analysis 1.9</a>). For one‐stage meta‐analyses, we used the Kaplan‐Meier method to calculate OS. We carried out the one‐stage meta‐analyses using Cox‐proportional hazards models, which address between‐study heterogeneity using a variety of approaches (<a href="./references#CD012007-bbs2-0013" title="BowdenJ , TierneyJF , SimmondsM , CopasAJ , HigginsJP .Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model. Research Synthesis Methods2011;2(3):150-62. [PMID: 26061783]">Bowden 2011</a>; <a href="./references#CD012007-bbs2-0021" title="DebrayTP , MoonsKG , AhmedI , KoffijbergH , RileyRD .A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Statistics in Medicine2013;32(18):3158-80. [PMID: 23307585]">Debray 2013</a>; <a href="./references#CD012007-bbs2-0023" title="deJongVM , MoonsKG , RileyRD , Tudur SmithC , MarsonAG , EijkemansMJ , et al.Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example. Research Synthesis Methods2020;11(2):148-68. [PMID: 31759339]">de Jong 2020</a>; <a href="./references#CD012007-bbs2-0059" title="SmithCT , WilliamsonPR , MarsonAG .Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Statistics in Medicine2005;24(9):1307-19. [PMID: 15685717]">Smith 2005</a>). We regarded the shared‐frailty model to be the most robust approach, as it most explicitly incorporates a (gamma‐distributed) random‐effects term to account for between‐study heterogeneity. As sensitivity analysis, we also employed stratified Cox models, which adjust for inter‐study heterogeneity by allowing participants from a particular study share a baseline hazard specific to that study (<a href="./references#CD012007-bbs2-0013" title="BowdenJ , TierneyJF , SimmondsM , CopasAJ , HigginsJP .Individual patient data meta-analysis of time-to-event outcomes: one-stage versus two-stage approaches for estimating the hazard ratio under a random effects model. Research Synthesis Methods2011;2(3):150-62. [PMID: 26061783]">Bowden 2011</a>; <a href="./references#CD012007-bbs2-0021" title="DebrayTP , MoonsKG , AhmedI , KoffijbergH , RileyRD .A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Statistics in Medicine2013;32(18):3158-80. [PMID: 23307585]">Debray 2013</a>; <a href="./references#CD012007-bbs2-0023" title="deJongVM , MoonsKG , RileyRD , Tudur SmithC , MarsonAG , EijkemansMJ , et al.Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example. Research Synthesis Methods2020;11(2):148-68. [PMID: 31759339]">de Jong 2020</a>; <a href="./references#CD012007-bbs2-0059" title="SmithCT , WilliamsonPR , MarsonAG .Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Statistics in Medicine2005;24(9):1307-19. [PMID: 15685717]">Smith 2005</a>). As a final sensitivity analysis, we also fitted marginal Cox models, which assume that no heterogeneity exists among studies. We calculated median follow‐up using the reverse Kaplan‐Meier method (<a href="./references#CD012007-bbs2-0055" title="SchemperM , SmithTL .A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials1996;17(4):343-6. [PMID: 8889347]">Schemper 1996</a>), and one‐stage meta‐analyses were conducted in Stata version 16·1 (<a href="./references#CD012007-bbs2-0062" title="Stata.Version 16. College Station, TX, USA: StataCorp, 2019. Available at www.stata.com.">Stata 2019</a>). </p> <div class="figure" id="CD012007-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA Flow Diagram" data-id="CD012007-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA Flow Diagram</p> </div> </div> </div> <div class="figure" id="CD012007-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012007-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD012007-sec-0037"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform subgroup analyses for the following factors.</p> <p> <ul id="CD012007-list-0012"> <li> <p>Studies conducted in Asia or with a majority of Asian women versus studies conducted in Western countries or with a majority of white women </p> </li> <li> <p>Metronomic (similar cumulative dosage) versus dose‐dense (increased cumulative dosage) dosing schedule </p> </li> <li> <p>Targeted therapy versus no targeted therapy</p> </li> <li> <p>Completeness of debulking surgery, residual disease &lt; 1 cm versus residual disease &gt; 1cm </p> </li> <li> <p>Intraperitoneal route (injection into the peritoneum (body cavity)) of administration versus non‐intraperitoneal </p> </li> </ul> </p> <p>We considered factors such as age, stage, type of intervention, length of follow‐up and risk of bias status in the interpretation of any heterogeneity. </p> </section> <section id="CD012007-sec-0038"> <h4 class="title">Sensitivity analysis</h4> <p>If we had identified sufficient studies, we would have assessed the robustness of primary outcome data by analyses of the type of publication (e.g. full‐text publication or abstract) and maturity of results. We would have performed sensitivity analyses for studies with unclear or high risk of bias. </p> </section> <section id="CD012007-sec-0039"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADEprofiler software to assist with the preparation of the summary of findings table (<a href="./references#CD012007-bbs2-0031" title="McMaster University (developed by Evidence Prime)GRADEPro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), accessed prior to 10 January 2021. Available at www.gradepro.org.">GRADEpro GDT</a>). The summary of findings table presents the review’s main findings in a table format, and provide key information about the best estimate of the magnitude of the effect, in relative terms, and absolute differences for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome, and the rating of the overall confidence in effect estimates for the comparisons in an outcome‐specific manner. </p> <p>We assessed the certainty of evidence as 'high', 'moderate', 'low' or 'very low' using the GRADE approach (<a href="./references#CD012007-bbs2-0032" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al.Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490-4.">GRADE Working Group 2004</a>; <a href="./references#CD012007-bbs2-0056" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.">Schünemann 2021</a>), which evaluates studies on five domains: study limitations (risk of bias), consistency, imprecision, indirectness and publication bias. Two review authors (NLS, RMG) independently rated the certainty for each outcome. They resolved any disagreements by appeal to a third (NYN) or fourth review author (DST) if necessary. </p> <p>The outcomes included in the summary of findings table are:</p> <p> <ul id="CD012007-list-0013"> <li> <p>progression‐free survival;</p> </li> <li> <p>overall survival;</p> </li> <li> <p>haematological adverse events: neutropenia;</p> </li> <li> <p>haematological adverse events: anaemia;</p> </li> <li> <p>neurological adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012007-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012007-sec-0040"></div> <section id="CD012007-sec-0041"> <h3 class="title">Description of studies</h3> <p>Overall, we identified 2469 potentially relevant records up to November 2021. Of these, we screened 1829 records after removing duplicates, and excluded 1807 records that did not fulfil our predefined inclusion criteria. We retrieved the remaining 22 publications as full‐text or abstract publications for more detailed evaluation. Of these references, we excluded three studies (reported in four references). In total, we identified four eligible studies reported in 18 references, which included a total of 3699 women, and formally included them in this review. </p> <section id="CD012007-sec-0042"> <h4 class="title">Results of the search</h4> <p>The PRISMA flow diagram is shown in <a href="#CD012007-fig-0001">Figure 1</a>. </p> </section> <section id="CD012007-sec-0043"> <h4 class="title">Included studies</h4> <p>This review included four studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). The <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study team supplied Individual participant data, and we extracted the data for all other studies from publications. All studies were fully published, with full‐text data available (<a href="./references#CD012007-sec-0112" title="">Characteristics of included studies</a>). </p> <section id="CD012007-sec-0044"> <h5 class="title">Design</h5> <p>Of the four studies, three were two‐armed RCTs (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>), and one was a three‐armed RCT (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>). One study recruited women between 2003 and 2005 (<a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>), whereas three studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>) recruited women between the period of 2008 to 2014. </p> </section> <section id="CD012007-sec-0045"> <h5 class="title">Participants</h5> <p>A total of 3717 women with newly diagnosed epithelial ovarian cancer were recruited across all studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>: 692 women, <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: 1566 women, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: 637 women, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: 822 women), and we included 3699 women in this review. In two studies, women with FIGO stages II to IV were eligible (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>), and in the remaining two studies women with FIGO stages IC to IV were eligible (<a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>). In the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study, women with stage II disease must have had no residual lesions larger than 1 cm in the greatest dimension. In the ICON8 study, women with stage IC‐IIA disease must have had mandatory high‐risk histological subtype. Amongst all studies, the majority of women presented with advanced stage (FIGO III‐IV) disease (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>: stage III 67%, stage IV 30%; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: stage III 58%, stage IV 16%, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: stage III 66%, stage IV 16%, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: stage III 59%, stage IV 24%). </p> <p>After primary or interval debulking surgery, the amount of residual disease was described in four studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>: absence of residual macroscopic disease = 24%, not fully assessed = 13%; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: residual &lt; 1 cm in size = 28%, residual disease &gt; 1cm in size = 14%, inoperable disease = 2%; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: residual disease &gt; 1 cm = 54%, residual disease &lt; 1cm in size = 46%, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: absence of macroscopic residual disease = 28%, residual disease ≤ 1cm = 12%, residual disease &gt; 1 cm = 23%, inoperable disease = 25%). </p> <p>The median age of women recruited in three studies was between 57 and 62 years (<a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: 57 years, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: 59.5 years, <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: 61 years). The median age of women recruited was not stated in <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> however, 46% of women were described as being of age &lt; 60 years. Three studies reported the distribution of participants' performance status (PS) by the Eastern Cooperative Oncology Group (ECOG) scale (<a href="./references#CD012007-bbs2-0049" title="OkenMM , CreechRH , TormeyDC , HortonJ , DavisTE , McFaddenET , et al.Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology1982;5(6):649-55.">Oken 1982</a>). The majority of women were of excellent performance status (ECOG 0 to 1) in three studies (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: 92%, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: 90%, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: 97%). The distribution of participants' performance status was not described in <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> however, all women had ECOG PS of 0 to 2. </p> <p>The histological subtype of epithelial ovarian cancer amongst women recruited was predominantly serous for all four studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>: 88%, <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: 72%, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: 56%, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: 70%). </p> </section> <section id="CD012007-sec-0046"> <h5 class="title">Location</h5> <p>The included studies were conducted in different geographic regions. Recruitment for <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> took place in the USA, Canada and South Korea, while <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> recruited from the UK, Australia, New Zealand, Mexico, Ireland and South Korea. <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> recruited women exclusively from Japan, while the <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> study recruited women from Italy and France. The ethnicity of recruited women was reported by two studies: <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> recruited exclusively Japanese women, while 85% of women on <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> were non‐Hispanic White. </p> </section> <section id="CD012007-sec-0047"> <h5 class="title">Intervention</h5> <p>Women in the included studies were treated with varying schedules of carboplatin combined with paclitaxel as front‐line treatment for epithelial ovarian cancer. The included studies utilised the following regimens. </p> <p> <ul id="CD012007-list-0014"> <li> <p><a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> ‐ intravenous carboplatin AUC 6 mg/mL + paclitaxel 175 mg/m<sup>2</sup> +/‐ bevacizumab 15 mg/kg every three weeks versus intravenous carboplatin AUC 6 mg/mL +/‐ bevacizumab 15 mg/kg every three weeks + paclitaxel 80 mg/m<sup>2</sup> weekly for six cycles </p> </li> <li> <p><a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> ‐ intravenous carboplatin AUC 5 mg/mL or 6 mg/mL + paclitaxel 175 mg/m<sup>2</sup> every three weeks versus intravenous carboplatin AUC 5 mg/mL or 6 mg/mL every three weeks + paclitaxel 80 mg/m<sup>2</sup> weekly versus intravenous carboplatin AUC 2 mg/mL + paclitaxel 60 mg/m<sup>2</sup> weekly for six cycles </p> </li> <li> <p><a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> ‐ intravenous carboplatin AUC 6 mg/mL + paclitaxel 180 mg/m<sup>2</sup> every three weeks versus intravenous carboplatin AUC 6 mg/mL every three weeks + paclitaxel 80 mg/m<sup>2</sup> weekly for six cycles </p> </li> <li> <p><a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> ‐ intravenous carboplatin AUC 6 mg/mL + paclitaxel 175 mg/m<sup>2</sup> every three weeks versus intravenous carboplatin AUC 2 mg/mL + paclitaxel 60 mg/m<sup>2</sup> weekly for six cycles </p> </li> </ul> </p> <p>None of the women received bevacizumab or targeted therapy in the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> and <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> studies, while 84% of women also received bevacizumab in the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study. </p> </section> <section id="CD012007-sec-0048"> <h5 class="title">Outcomes</h5> <section id="CD012007-sec-0049"> <h6 class="title">Primary outcome measures</h6> <p>All studies analysed PFS, which was defined similarly amongst included studies as the time from date of randomisation to death or disease progression. The median follow‐up for PFS outcomes was 28.5 months (range 22.3 to 36.8 months) in the four included studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). All studies analysed OS, and the median observation times for OS were 76.8 months (<a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>), 28 months (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>), 36.8 months (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>), and 22.3 months (<a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). No P values were available for the analyses of OS in three studies, as these analyses remained immature with fewer events occurring than were prespecified (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a><a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). All studies measured and reported toxicity and safety. </p> </section> <section id="CD012007-sec-0050"> <h6 class="title">Secondary outcome measures</h6> <p>All studies reported quality of life, adverse events and treatment discontinuation.</p> <section id="CD012007-sec-0051"> <p><b>Quality of life measures</b></p> <p>Three studies utilised the Functional Assessment of Cancer Therapy (FACT)‐Ovary (FACT‐O) questionnaire (<a href="./references#CD012007-bbs2-0011" title="Basen-EngquistK , Bodurka-BeversD , FitzgeraldMA , WebsterK , CellaD , HuS , et al.Reliability and validity of the functional assessment of cancer therapy-ovarian. Journal of Clinical Oncology2001;19(6):1809-17.">Basen‐Engquist 2001</a>) for assessing changes to women’ quality of life (QoL) while receiving study treatments (<a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). The <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study assessed quality of life measures using the European Organisation for Research and Treatment of Cancer (EORTC) Quality‐of‐Life Questionnaire (QLQ)‐C30 (<a href="./references#CD012007-bbs2-0009" title="AaronsonNK , AhmedzaiS , BergmanB , BullingerM , CullA , DuezNJ , et al.The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst1993;85(5):365-76.">Aaronson 1993</a>), QLQ‐OV28 (<a href="./references#CD012007-bbs2-0033" title="GreimelE , BottomleyA , CullA , WaldenstromAC , ArrarasJ , ChauvenetL , et al.An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. European Journal of Cancer2003;39(10):1402-8.">Greimel 2003</a>), and EuroQol Group EQ5D (<a href="./references#CD012007-bbs2-0026" title="EuroQol Group.EuroQol - a new facility for the measurement of health-related quality of life. Health Policy1990;16(3):199-208.">EuroQol 1990</a>) tools. The time points for assessing QoL differed amongst included studies. In the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study, assessments were performed at baseline, prior to cycle four, three weeks after cycle six, 36 weeks after cycle one and 63 weeks after cycle one. In the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study, QoL assessment was performed at baseline, before each chemotherapy cycle and then six‐weekly until nine months, three‐monthly until two years and six‐monthly until five years. In the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> study, QoL assessment was performed at baseline, after cycles three and six and at 12 months after randomisation. In the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study, QoL assessment was performed at baseline, before each chemotherapy cycle and then every six weeks until nine months, every three months until two years and every six months until five years. In the <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> study, QoL assessment was performed at baseline, then every week for nine weeks. </p> </section> <section id="CD012007-sec-0052"> <p><b>Toxicity</b></p> <p>Three studies scored toxicity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>), whereas the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> study used CTCAE version 2.0 (<a href="./references#CD012007-bbs2-0019" title="National Cancer Institute (NCI).Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC) v5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm (publication # 09-7473) (accessed 30 August 2021).">CTCAE 2018</a>). </p> </section> </section> </section> </section> <section id="CD012007-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies after evaluation of their full‐text publications. The reasons for their exclusion were as follows. </p> <p> <ul id="CD012007-list-0015"> <li> <p>We excluded the <a href="./references#CD012007-bbs2-0007" title="ShenK , LiMD , FengYJ , MaD , LiZT , XieX , et al.A multicenter randomized clinical trial of weekly paclitaxel and carboplatin vs three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer. Chinese Medical Journal2005;85(30):2099-103. ">Shen 2005</a> study due to concerns regarding its reported methods. Under 1:1 randomisation, it would be expected that 50% of the total 125 women to be allocated to each arm on this study. However, the study reported having 51 and 74 women in each arm, respectively. This was very unlikely to be due to chance. Under the exact binomial test, the chance of having 51 and 74 women in each arm, assuming 1:1 randomisation, is 0.86% </p> </li> <li> <p>The <a href="./references#CD012007-bbs2-0005" title="DuZ , MaX .Dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin treatment for stage II-IV ovarian cancer patients. Bangladesh Journal of Pharmacology2015;10(3):489-93. ">Du 2015</a> study was not suitably informative, as it did not report the number of death events, making it impossible to accurately extract PFS and OS events from reported data. Furthermore, severity of toxicity was not reported using CTCAE criteria, so this could not be analysed with the included studies. </p> </li> <li> <p>One study utilised carboplatin AUC 2 mg/mL + paclitaxel 60 mg/m<sup>2</sup> weekly on days 1, 8 and 15 of a four‐week cycle as an intervention arm. The review authors agreed that the dose‐intensity of paclitaxel on this regimen was too low for it to be included (<a href="./references#CD012007-bbs2-0006" title="FalandryC , RousseauF , Mouret-ReynierMA , TinquautF , LorussoD , HerrstedtJ , et al.Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin plus Paclitaxel for Vulnerable Older Adult Women with Ovarian Cancer: a Randomized Clinical Trial. JAMA Oncology2021;7(6):853–61. FalandryC , SavoyeAM , StefaniL , TinquautF , LorussoD , HerrstedtJ , et al.EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): a GCIG-ENGOT-GINECO study. Journal of Clinical Oncology2019;37(15 Suppl):5508. ">Falandry 2021</a>). </p> </li> </ul> </p> <p>Excluded studies are described further in <a href="./references#CD012007-sec-0113" title="">Characteristics of excluded studies</a>. </p> <section id="CD012007-sec-0054"> <h5 class="title">Ongoing studies</h5> <p>We identified one relevant ongoing study. <a href="./references#CD012007-bbs2-0008" title="ClampA .A trial looking at chemotherapy with or without bevacizumab for advanced ovarian cancer (ICON8B). www.icon8trial.org/patients/icon8b-trial-summary/ (accessed 28 June 2021). ">ICON8B</a> (CRUK/13/023) is an international RCT randomising women with newly‐diagnosed advanced ovarian, fallopian tube or primary peritoneal cancer to one of two arms; group B1: intravenous carboplatin, paclitaxel and bevacizumab every three weeks for 18 weeks followed by bevacizumab continuing alone for approximately 11 months, or group B2: intravenous carboplatin every three weeks, paclitaxel every week and bevacizumab every three weeks for 18 weeks followed by bevacizumab continuing alone for approximately 11 months. This study has completed recruitment. However, study results have not yet been reported and are expected to be released in 2023. </p> </section> </section> </section> <section id="CD012007-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessments for included studies are summarised in <a href="./references#CD012007-sec-0112" title="">Characteristics of included studies</a>, <a href="#CD012007-fig-0002">Figure 2</a> and <a href="#CD012007-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012007-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012007-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012007-sec-0056"> <h4 class="title">Allocation</h4> <p>All studies used central allocation to allocate women to treatment. All studies which described central allocation utilised a computer‐generated central minimisation procedure to ensure that equal numbers of women received each study treatment based on prespecified stratification factors (low risk of bias). All studies utilised disease status with respect to cytoreduction procedure and participant performance status as stratification factors. Three studies used disease stage as an additional stratification factor (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>). Only one study stratified EOC histotype into subgroups 'serous/others' versus 'clear cell/mucinous' (<a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>). As the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study allowed women to opt for bevacizumab therapy, the decision whether to use bevacizumab therapy was an additional stratification factor for this study. </p> </section> <section id="CD012007-sec-0057"> <h4 class="title">Blinding</h4> <p>None of the studies blinded participants and investigators to the allocated treatment. OS outcomes would not be influenced by the presence or absence of blinding, therefore performance and detection bias for this outcome would be low. However, the lack of blinding may affect other study outcomes such as PFS and QoL. Therefore, we judged all studies to be 'unclear' for this domain. </p> </section> <section id="CD012007-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies described missing outcome data in detail (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). Missing outcome data numbers were balanced across groups in <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> and <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>, but were higher in group 2 of <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> compared to groups 1 and 3 (12 women lost to follow‐up or withdrawn compared to four and five women each in groups 1 and 3, respectively). <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>, <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> and <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> analysed all randomised women, whereas <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> excluded women who had withdrawn consent immediately after randomisation. As the absolute numbers of women who had missing data was small, and detailed descriptions were provided in three of four studies, it is unlikely that the missing data introduced bias to the main meta‐analysis. Thus, we assessed attrition bias to be ‘low’. </p> </section> <section id="CD012007-sec-0059"> <h4 class="title">Selective reporting</h4> <p>All studies reported prespecified primary outcomes (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>: PFS; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: PFS, OS; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: PFS; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: PFS, QoL). Therefore, the risk of reporting bias was low. </p> </section> <section id="CD012007-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other potential sources of bias.</p> </section> </section> <section id="CD012007-sec-0061"> <h3 class="title" id="CD012007-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD012007-tbl-0001"><b>Summary of findings 1</b> Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer</a> </p> <section id="CD012007-sec-0062"> <h4 class="title">Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment </h4> <section id="CD012007-sec-0063"> <h5 class="title">Primary outcome</h5> <section id="CD012007-sec-0064"> <h6 class="title">Progression free survival (PFS)</h6> <section id="CD012007-sec-0065"> <p><b>Participants</b></p> <p>All studies provided information on this outcome, and this analysis included 3639 participants.. </p> </section> <section id="CD012007-sec-0066"> <p><b>Results</b></p> <p>The main analysis showed a significant difference in PFS between weekly and tri‐weekly paclitaxel dosing (HR 0.89, 95% CI 0.81 to 0.98; P = 0.02; 4 studies, 3699 participants; moderate‐certainty evidence; <a href="./references#CD012007-fig-0006" title="">Analysis 1.1</a>; <a href="./full#CD012007-tbl-0001">summary of findings Table 1</a>). This indicates that weekly paclitaxel reduces the hazard rate of progression or death by 11% (with 95% confidence that the true effect size is between 2% and 19%). There was low heterogeneity between studies (Chi<sup>2</sup> = 4.37, P = 0.22, I<sup>2</sup> = 31%). <a href="#CD012007-fig-0004">Figure 4</a> shows sensitivity analysis that utilised IPD from one study; improved PFS for weekly versus tri‐weekly paclitaxel was evident. Shared‐frailty (random‐effects) HR for PFS of weekly versus tri‐weekly paclitaxel dosing was 0.90 (95% CI 0.83 to 0.97; P = 0.0076; <a href="#CD012007-fig-0004">Figure 4</a>E). </p> <div class="figure" id="CD012007-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="original image" data-id="CD012007-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-04.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD012007-sec-0067"> <p><b>Subgroup analysis</b></p> <p>The test for subgroup differences showed no statistical difference when the following subgroup analyses were conducted. </p> <p> <ul id="CD012007-list-0016"> <li> <p>Residual disease (P = 0.74; absent: one study; ≤1cm: three studies; &gt; 1cm: three studies; no surgery performed: one study; <a href="./references#CD012007-fig-0007" title="">Analysis 1.2</a>). </p> </li> <li> <p>FIGO stage of disease (P = 0.91; stage I or II: three studies; stage III or IV: two studies; stage I: one study; stage II: two studies; stage III: three studies; stage IV: three studies; <a href="./references#CD012007-fig-0008" title="">Analysis 1.3</a>). </p> </li> <li> <p>ECOG performance status (P = 0.78; ECOG 0 or 1: two studies; ECOG 2, 3 or 4: four studies; ECOG 0: three studies; ECOG 1: three studies; ECOG 2: three studies; <a href="./references#CD012007-fig-0009" title="">Analysis 1.4</a>). </p> </li> <li> <p>Bevacizumab receipt (P = 0.15; no bevacizumab received: three studies; bevacizumab received: one study; <a href="./references#CD012007-fig-0010" title="">Analysis 1.5</a>). </p> </li> <li> <p>Age distribution (P = 0.67; &lt; 60 years: two studies; ≥ 60 years: three studies; &lt; 70 years: three studies; ≥ 70 years: two studies; <a href="./references#CD012007-fig-0011" title="">Analysis 1.6</a>). </p> </li> <li> <p>Epithelial ovarian cancer histotype (P = 0.30; serous: two studies; non‐serous: two studies; <a href="./references#CD012007-fig-0013" title="">Analysis 1.8</a>). It is noted that the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> study stratified histology into the following subgroups: serous/others versus clear‐cell/mucinous. We have included the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> data in this subgroup analysis assuming that the proportion of other histologies in the serous/others subgroup is small. </p> </li> </ul> </p> <p>The test for subgroup differences showed a statistical difference when the following subgroup analysis was conducted. </p> <p> <ul id="CD012007-list-0017"> <li> <p>Carboplatin dosing (P = 0.04; weekly carboplatin dosing: two studies; tri‐weekly carboplatin dosing: three studies; <a href="./references#CD012007-fig-0012" title="">Analysis 1.7</a>). </p> </li> </ul> </p> <p>There was low heterogeneity (I<sup>2</sup> = 36%) between results from studies within the tri‐weekly carboplatin subgroup. However, since the number of studies included in the analysis was small, we do not have enough evidence to confidently conclude that there is a true subgroup effect. </p> </section> </section> <section id="CD012007-sec-0068"> <h6 class="title">Overall survival (OS)</h6> <section id="CD012007-sec-0069"> <p><b>Participants</b></p> <p>All studies provided information on this outcome, and this analysis included 3699 participants. </p> </section> <section id="CD012007-sec-0070"> <p><b>Results</b></p> <p>The main analysis showed no significant difference in OS between weekly and tri‐weekly paclitaxel dosing (HR 0.92, 95% CI 0.79 to 1.06; P = 0.25; 4 studies, 3699 participants; high‐certainty evidence; <a href="./references#CD012007-fig-0014" title="">Analysis 1.9</a>; <a href="./full#CD012007-tbl-0001">summary of findings Table 1</a>). There was low heterogeneity between studies (Chi<sup>2</sup> = 4.86, P = 0.18, I<sup>2</sup> = 38%). On sensitivity analysis that utilised IPD from one study (<a href="#CD012007-fig-0005">Figure 5</a>), no significant difference in OS for weekly versus tri‐weekly paclitaxel was evident. The shared‐frailty (random‐effects) HR of weekly versus tri‐weekly paclitaxel dosing was 0.90 (95% CI 0.81 to 1.01; P = 0.073; <a href="#CD012007-fig-0005">Figure 5</a>E). However, it is worth noting that the upper limit of the 95% CI of the shared‐frailty HR was approaching statistical significance. </p> <div class="figure" id="CD012007-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="original image" data-id="CD012007-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-05.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD012007-sec-0071"> <p><b>Subgroup analysis</b></p> <p>The test for subgroup differences showed no statistical difference when the following subgroup analyses were conducted. </p> <p> <ul id="CD012007-list-0018"> <li> <p>Residual disease (P = 0.92; ≤ 1cm: one study; &gt; 1cm: one study; <a href="./references#CD012007-fig-0015" title="">Analysis 1.10</a>). </p> </li> <li> <p>FIGO stage of disease (P = 0.79; stage I or II: two studies; stage I: one study; stage II: two studies; stage III, two studies; stage IV: two studies; <a href="./references#CD012007-fig-0016" title="">Analysis 1.11</a>). </p> </li> <li> <p>ECOG performance status (P = 0.70; ECOG 0 or 1: two studies; ECOG 2, 3 or 4: two studies; <a href="./references#CD012007-fig-0017" title="">Analysis 1.12</a>). </p> </li> <li> <p>Bevacizumab receipt (P = 0.90; no bevacizumab received: three studies; mixed population of women who received/did not receive bevacizumab: one study; <a href="./references#CD012007-fig-0018" title="">Analysis 1.13</a>). </p> </li> <li> <p>Age distribution (P = 0.69; age &lt; 60 years: one study; age ≥ 60: one study; <a href="./references#CD012007-fig-0019" title="">Analysis 1.14</a>). </p> </li> <li> <p>Carboplatin dosing (P = 0.30; weekly carboplatin dosing: two studies; tri‐weekly carboplatin dosing: two studies; <a href="./references#CD012007-fig-0020" title="">Analysis 1.15</a>). </p> </li> <li> <p>Epithelial ovarian cancer histotype (P = 0.71; serous: two studies; non‐serous: two studies; <a href="./references#CD012007-fig-0021" title="">Analysis 1.16</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012007-sec-0072"> <h6 class="title">Neutropenia</h6> <section id="CD012007-sec-0073"> <p><b>Participants</b></p> <p>All studies reported on this outcome, and this analysis included 3639 participants.</p> </section> <section id="CD012007-sec-0074"> <p><b>Results</b></p> <p>We did not observe any difference in grade 3 or 4 neutropenia between weekly and tri‐weekly paclitaxel dosing (RR 1.11, 95% CI 0.86 to 1.43; P = 0.41; 4 studies, 3699 participants; moderate‐certainty evidence; <a href="./references#CD012007-fig-0022" title="">Analysis 1.17</a>; <a href="./full#CD012007-tbl-0001">summary of findings Table 1</a>). There was a high degree of heterogeneity between studies (Chi<sup>2</sup> = 73.70, P &lt; 0.00001, I<sup>2</sup> = 96%). </p> </section> </section> </section> <section id="CD012007-sec-0075"> <h5 class="title">Secondary outcome:</h5> <section id="CD012007-sec-0076"> <h6 class="title">Adverse events</h6> <section id="CD012007-sec-0077"> <p><b>Participants</b></p> <p>All four studies (3639 participants) reported the following high grade (grade 3 or 4) acute adverse events: thrombocytopenia, vomiting and diarrhoea. Three studies (2956 participants) reported high grade fatigue (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). Two studies (2365 participants) reported any‐grade alopecia, acute high‐grade transaminitis, anorexia and mucositis (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). These studies also reported acute high‐grade leucopenia (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>). Two studies (2157 participants) reported acute high‐grade myalgia, arthralgia and hypersensitivity (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>). </p> </section> <section id="CD012007-sec-0078"> <p><b>Results</b></p> <p>We noted a difference between weekly and tri‐weekly paclitaxel for the following adverse events, favouring tri‐weekly paclitaxel. </p> <p> <ul id="CD012007-list-0019"> <li> <p>Anaemia (452 versus 248 events; RR 1.57, 95% CI 1.12 to 2.20; P = 0.002; 4 studies, 3639 participants; high‐certainty evidence; <a href="./references#CD012007-fig-0024" title="">Analysis 1.19</a>; <a href="./full#CD012007-tbl-0001">summary of findings Table 1</a>). There was a high degree of heterogeneity between studies (Chi<sup>2</sup> = 14.47, P = 0.002, I<sup>2</sup> = 79%). </p> </li> <li> <p>Treatment discontinuation (190 versus 98 events; RR 1.86, 95% CI 1.42 to 2.42; P&lt;0.00001; 3 studies, 2108 participants; <a href="./references#CD012007-fig-0039" title="">Analysis 1.34</a>). </p> </li> <li> <p>Dose delays (1081 versus 516 events; RR 1.57, 95% CI 2.21 to 2.03; P = 0.0006; 3 studies, 3050 participants; <a href="./references#CD012007-fig-0040" title="">Analysis 1.35</a>). We observed a high level of heterogeneity between studies (Chi<sup>2</sup> = 21.27, P&lt;0.0001, I<sup>2</sup> = 91%). </p> </li> <li> <p>Dose omissions (465 versus 78 events; RR 2.98, 95% CI 2.40 to 3.70; P&lt;0.00001; 1 study, 1566 participants; <a href="./references#CD012007-fig-0040" title="">Analysis 1.35</a>). </p> </li> </ul> </p> <p>We did not note any differences between weekly and tri‐weekly paclitaxel for the following adverse events. </p> <p> <ul id="CD012007-list-0020"> <li> <p>Febrile neutropenia (<a href="./references#CD012007-fig-0023" title="">Analysis 1.18</a>) </p> </li> <li> <p>Grade 3 or 4 leucopenia (<a href="./references#CD012007-fig-0025" title="">Analysis 1.20</a>) </p> </li> <li> <p>Grade 3 or 4 thrombocytopenia (<a href="./references#CD012007-fig-0026" title="">Analysis 1.21</a>) </p> </li> <li> <p>Grade 3 or 4 transaminitis (<a href="./references#CD012007-fig-0027" title="">Analysis 1.22</a>) </p> </li> <li> <p>Grade 3 or 4 fatigue (<a href="./references#CD012007-fig-0028" title="">Analysis 1.23</a>) </p> </li> <li> <p>Grade 3 or 4 myalgia (<a href="./references#CD012007-fig-0029" title="">Analysis 1.24</a>) </p> </li> <li> <p>Grade 3 or 4 arthralgia (<a href="./references#CD012007-fig-0030" title="">Analysis 1.25</a>) </p> </li> <li> <p>Grade 3 or 4 anorexia (<a href="./references#CD012007-fig-0031" title="">Analysis 1.26</a>) </p> </li> <li> <p>Grade 3 or 4 diarrhoea (<a href="./references#CD012007-fig-0032" title="">Analysis 1.27</a>) </p> </li> <li> <p>Grade 3 or 4 vomiting (<a href="./references#CD012007-fig-0033" title="">Analysis 1.28</a>) </p> </li> <li> <p>Grade 2 or higher neuropathy, not otherwise specified (<a href="./references#CD012007-fig-0034" title="">Analysis 1.29</a>) </p> </li> <li> <p>Grade 2 or higher sensory neuropathy (<a href="./references#CD012007-fig-0034" title="">Analysis 1.29</a>) </p> </li> <li> <p>Grade 2 or higher motor neuropathy (<a href="./references#CD012007-fig-0034" title="">Analysis 1.29</a>) </p> </li> <li> <p>Grade 3 or 4 neuropathy, not otherwise specified (<a href="./references#CD012007-fig-0035" title="">Analysis 1.30</a>) </p> </li> <li> <p>Grade 3 or 4 sensory neuropathy (<a href="./references#CD012007-fig-0035" title="">Analysis 1.30</a>) </p> </li> <li> <p>Grade 3 or 4 motor neuropathy (<a href="./references#CD012007-fig-0035" title="">Analysis 1.30</a>) </p> </li> <li> <p>Any‐grade alopecia (RR 0.87, 95% CI 0.65‐1.17; P = 0.36; 2 studies, 2330 participants; <a href="./references#CD012007-fig-0036" title="">Analysis 1.31</a>) </p> </li> <li> <p>Any‐grade mucositis (<a href="./references#CD012007-fig-0037" title="">Analysis 1.32</a>) </p> </li> <li> <p>Grade 3 or 4 hypersensitivity (<a href="./references#CD012007-fig-0038" title="">Analysis 1.33</a>) </p> </li> <li> <p>Dose reductions (<a href="./references#CD012007-fig-0040" title="">Analysis 1.35</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012007-sec-0079"> <h6 class="title">Quality of Life</h6> <section id="CD012007-sec-0080"> <p><b>Participants</b></p> <p>A total of 3346 participants were evaluated for participant‐reported QoL outcomes across four studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> 560 participants; <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> 1540 participants; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: 637 participants, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: 609 participants). </p> </section> <section id="CD012007-sec-0081"> <p><b>Results</b></p> <p>QoL analysis described by three of the four studies appeared to be concordant in suggesting no clinically significant deterioration in QoL analysis overall when paclitaxel was dosed weekly compared to tri‐weekly. </p> <p>In the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study (560 participants), after adjusting for potential confounders, weekly paclitaxel was associated with lower FACT‐OTrial Outcome Index (TOI) scores (suggesting lower QoL) during the period of assessment, compared to those receiving paclitaxel tri‐weekly. However, the maximal decrease in FACT‐O TOI score was only 2.7 points (97.5% CI, ‐5.44 to 0.02, P = 0.02), occurring after cycle six of chemotherapy; we did not consider this to be clinically significant. However, participant‐reported neurotoxicity (peripheral neuropathy in particular), was higher amongst women receiving weekly compared to tri‐weekly paclitaxel, and this persisted during the study period. </p> <p>In the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study (1540 participants), cross‐sectional comparison between study groups showed marginally lower global health scores for weekly paclitaxel dosing groups compared to the tri‐weekly paclitaxel dosing group. This difference was statistically significant until nine months after randomisation, but was deemed to be clinically insignificant. At the nine‐month follow‐up after randomisation, we did not note any further differences between the three treatment groups with cross‐sectional analysis. This likely reflects slower improvements in QoL for women receiving weekly paclitaxel regimens compared to tri‐weekly dosing; however, eventual recovery for all groups was likely to be similar by nine months. Slightly worse fatigue and peripheral neuropathy were reported by women receiving weekly paclitaxel compared to tri‐weekly dosing. In particular, peripheral neuropathy for women receiving weekly paclitaxel was reported to be more gradual in onset, but more prolonged beyond the end of treatment, compared to tri‐weekly dosing in this study. </p> <p>In the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> study (637 participants), we did not observe any difference in overall QoL between weekly paclitaxel and standard chemotherapy groups at 12 months after randomisation. However, QoL by the FACT‐Taxane subscale was lower in the weekly paclitaxel dosing group compared to standard chemotherapy group (P = 0.02). This reflects the worse neurotoxicity reported by women in the weekly paclitaxel group, which negatively impacted upon QoL. </p> <p>In comparison, the <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> study (609 participants) reported no deterioration of QoL by overall FACT‐O scoring for women receiving weekly paclitaxel compared to tri‐weekly dosing, including for the FACT‐Taxane neurotoxicity subscale. In all QoL analyses, weekly paclitaxel was favoured in treatment‐by‐time interaction (P &lt; 0.0001). This difference compared to the prior two studies may reflect the lower cumulative dose of paclitaxel when dosed weekly in the <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> study (180 mg/m<sup>2</sup> per cycle), compared to the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>, and <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> studies (240 mg/m<sup>2</sup> per cycle), although the precise mechanism for paclitaxel neurotoxicity is still not fully understood. </p> </section> <section id="CD012007-sec-0082"> <p><b>Subgroup analysis</b></p> <p>We could not conduct subgroup analyses for the secondary outcome of QoL due to heterogeneity in the available data. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012007-sec-0083" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012007-sec-0083"></div> <section id="CD012007-sec-0084"> <h3 class="title" id="CD012007-sec-0084">Summary of main results</h3> <p>In this systematic review and meta‐analysis, we analysed the efficacy and toxicity profile of weekly paclitaxel compared to tri‐weekly paclitaxel when combined with carboplatin for the first‐line treatment of ovarian cancer. The results are summarised in the <a href="./full#CD012007-tbl-0001">summary of findings Table 1</a>. </p> <p>Moderate‐certainty evidence found that dosing paclitaxel weekly improved PFS, compared to tri‐weekly dosing; this was consistent on aggregate data meta‐analysis, as well as on pooled IPD meta‐analysis. Moderate‐evidence found no difference in the risk for grade 3 or 4 neutropenia or febrile neutropenia between both dosing schedules. Low‐certainty evidence found no difference in the risk for grade 3 or 4 neuropathy between both dosing schedules. However, high‐certainty evidence found an increased risk of grade 3 or 4 anaemia with weekly paclitaxel and no improvement in OS, compared to tri‐weekly paclitaxel dosing. </p> <p>We used a qualitative synthesis to assess QoL due to heterogeneity in the QoL instruments used by the studies, assessment time points and outcome reporting. We found no clinically significant deterioration in QoL for participants receiving weekly compared to tri‐weekly paclitaxel. </p> </section> <section id="CD012007-sec-0085"> <h3 class="title" id="CD012007-sec-0085">Overall completeness and applicability of evidence</h3> <p>All studies included in the main analysis were published in full. Reliable conclusions could be drawn from the primary outcome measure of PFS, which had mature data reported by all studies included in the main analysis. It is worth noting that the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> and <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a> studies were statistically powered solely for their PFS endpoint and relatively few OS events were included at the time of study publication. However, this would not affect the reliability of the OS conclusions drawn from our meta‐analysis. All studies reported toxicity outcomes in detail, providing sufficient data for us to draw conclusions. We were not able to reliably analyse certain a priori subgroup analyses determined at the time of protocol writing, such as ethnicity (Asian participants versus non‐Asian participants) and the receipt of targeted therapy (addition of targeted therapy versus no addition of targeted therapy), as there was only one study each reporting data on these subgroups (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>). </p> <p>For the secondary outcome of QoL, we synthesised the data qualitatively as QoL outcome reporting amongst including studies was heterogenous. Missing data, in terms of standard deviation, standard error, 95% confidence intervals at specific time points, as well as measures of uncertainty versus dispersion, led to difficulties in aggregating the data in a quantitative meta‐analysis. Furthermore, heterogeneity existed in terms of the reporting timeframe of QoL assessment, e.g. end of the cycle versus number of weeks after randomisation, as well as the QoL instrument scales and subscales utilised by included studies. We also observed differences in the reporting of central tendencies. Therefore, we undertook qualitative synthesis of QoL data instead of the planned meta‐analysis. </p> <section id="CD012007-sec-0086"> <h4 class="title">Histological subtype</h4> <p>Epithelial ovarian cancer is a heterogenous disease with well‐defined distinct histological subtypes, which are associated with different clinico‐pathological features, response to chemotherapy and prognosis. We did not impose any restrictions based on histological subtype when including studies for analysis. All four included studies recruited a majority of women with high‐grade serous subtype epithelial ovarian cancer (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>: 88%, <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>: 68%, <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>: 56%, <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>: 70%), whereas other histological types, such as clear cell or mucinous cancer, were less well‐represented. </p> </section> <section id="CD012007-sec-0087"> <h4 class="title">Ethnicity</h4> <p>Survival amongst women with epithelial ovarian cancer has been observed to vary by ethnicity and country. A recent population‐based study of 7914 women diagnosed with epithelial ovarian cancer showed an improved five‐year disease specific survival for Asian women compared to Caucasian women (54.1% versus 46.1%, P = 0.001) (<a href="./references#CD012007-bbs2-0028" title="FuhKC , JavaJJ , ChanJK , KappDS , MonkBJ , BurgerRA , et al.Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: an NRG Oncology/GOG Ancillary study of 7914 patients. Gynecologic Oncology2019;154(2):420-5.">Fuh 2019</a>). Possible pharmacogenetic differences between ethnic groups has often been cited as the likely reason underlying observed differences in treatment response and toxicity outcomes. Ethnic differences in the distribution of genotypes of enzymes required for paclitaxel metabolism have been described (<a href="./references#CD012007-bbs2-0029" title="GandaraDR , KawaguchiT , CrowleyJ , MoonJ , FuruseK , KawaharaM , et al.Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of Clinical Oncology2009;27(21):3540-6.">Gandara 2009</a>), though the precise mechanisms for how these pharmacogenetic variations impact upon clinical outcomes has yet to be fully elucidated. In our study, subgroup analysis by ethnicity was not possible as only one study recruited an all‐Japanese population (<a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>), and the remaining three studies did not report on outcomes by ethnic group. </p> </section> <section id="CD012007-sec-0088"> <h4 class="title">Role of bevacizumab</h4> <p>The addition of bevacizumab to first‐line tri‐weekly carboplatin and paclitaxel is well recognised as an option for first‐line therapy of epithelial ovarian cancer (<a href="./references#CD012007-bbs2-0048" title="National Comprehensive Cancer Network.Ovarian cancer including fallopian tube cancer and primary peritoneal cancer Version 1; 26 February 2021. Available at www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.">National Comprehensive Cancer Network 2021</a>). Two RCTs have demonstrated improvements in PFS when bevacizumab is added to tri‐weekly carboplatin and paclitaxel (<a href="./references#CD012007-bbs2-0050" title="OzaAM , CookAD , PfistererJ , EmbletonA , LedermannJA , Pujade-LauraineE , et al.Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncology2015;16(8):928-36.">Oza 2015</a>; <a href="./references#CD012007-bbs2-0065" title="TewariKS , BurgerRA , EnserroD , NorquistBM , SwisherEM , BradyMF , et al.Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. Journal of Clinical Oncology2019;37(26):2317-28.">Tewari 2019</a>). The role of bevacizumab addition in women receiving weekly paclitaxel combined with carboplatin in first‐line therapy of epithelial ovarian cancer is poorly established. In the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study, 84% of enrolled women received bevacizumab, and in the 16% of women (112 participants) who did not receive bevacizumab, weekly paclitaxel was associated with longer PFS compared to tri‐weekly dosing (14.2 versus 10.3 months, HR 0.62). In the present meta‐analysis, the test for subgroup differences indicates no statistically significant subgroup effect (P = 0.15), suggesting that bevacizumab does not modify the effect of weekly paclitaxel dosing in comparison to tri‐weekly dosing. However, only one study contributed data to the subgroup of participants who had received bevacizumab (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>): 80 participants), meaning that the analysis may not be able to detect subgroup differences. It is interesting to note that the pooled effect estimates for participants not receiving bevacizumab favours weekly paclitaxel dosing. As such, these results should not be applied to women receiving bevacizumab in first‐line therapy. </p> </section> <section id="CD012007-sec-0089"> <h4 class="title">Neoadjuvant therapy</h4> <p>Only the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study has published prospective data from a post‐hoc exploratory analysis comparing objective responses (by Response Evaluation Criteria in Solid Tumours (RECIST) or GCIG criteria between weekly paclitaxel and tri‐weekly paclitaxel dosing when combined with tri‐weekly carboplatin in this setting (<a href="./references#CD012007-bbs2-0047" title="MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet. Oncology2021;22(2):277-88. [PMID: 33357510]">Morgan 2021</a>). This study did not observe any difference in the rate of RECIST complete or partial response, nor of complete cytoreduction, between weekly and tri‐weekly paclitaxel groups. Contrary to this, other retrospective studies have suggested that paclitaxel 80 mg/m<sup>2</sup> weekly combined with carboplatin tri‐weekly facilitates higher rates of pathological complete response and complete resection with no residual disease in women undergoing interval debulking surgery after neoadjuvant chemotherapy (<a href="./references#CD012007-bbs2-0012" title="BeckerDA , ThomasED , GilbertAL , BooneJD , Straughn JM Jr, HuhWK , et al.Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma. Gynecol Oncol2016;142(1):25-9.">Becker 2016</a>; <a href="./references#CD012007-bbs2-0025" title="EbataT , YunokawaM , BunS , ShimomuraA , ShimoiT , KodairaM , et al.Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas. Cancer Chemother Pharmacol2016;78(6):1283-8.">Ebata 2016</a>). In the present meta‐analysis, only one of the included studies reported data on PFS and OS according to timing of surgery (interval versus primary debulking surgery) (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>). As such, these results may not be applicable to women receiving neoadjuvant therapy. </p> </section> <section id="CD012007-sec-0090"> <h4 class="title">Cost‐effectiveness</h4> <p>Cost‐effectiveness of weekly versus tri‐weekly paclitaxel dosing in combination with carboplatin was not an a priori analysis planned at the time of protocol writing for this systematic review. However, we note that two studies have published cost‐effectiveness analyses of weekly versus tri‐weekly paclitaxel dosing based on results of the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> (<a href="./references#CD012007-bbs2-0057" title="SeagleBL , ShahabiS .Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: an economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic Oncology2017;145(1):9-14.">Seagle 2017</a>) and <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> (<a href="./references#CD012007-bbs2-0020" title="DaltonHJ , YuX , HuL , KappDS , BenjaminI , Monk BJ , et al.An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecologic Oncology2012;124(2):199-204.">Dalton 2012</a>) studies. The first study by Dalton and colleagues utilised a Markov decision model (<a href="./references#CD012007-bbs2-0015" title="BriggsA , SculpherM .An introduction to Markov modelling for economic evaluation. Pharmacoeconomics1998;13(4):397-409.">Briggs 1998</a>) to estimate an acceptable incremental cost‐effectiveness ratio (ICER) per progression‐free life‐year saved (PFLYS), using survival estimates from the <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a> study and costs of drugs, growth colony‐stimulating factors and transfusions from Medicare reimbursement data. Costs reported by <a href="./references#CD012007-bbs2-0020" title="DaltonHJ , YuX , HuL , KappDS , BenjaminI , Monk BJ , et al.An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecologic Oncology2012;124(2):199-204.">Dalton 2012</a> were updated to the year of equivalence (2021) using readily available on‐line tools (<a href="./references#CD012007-bbs2-0038" title="Inflation Tool 2021. www.inflationtool.com (accessed 9 December 2021).">Inflation Tool 2021</a>). Despite the higher costs per cycle of chemotherapy for weekly paclitaxel compared with tri‐weekly paclitaxel dosing (US dollar (USD) 1008 per cycle versus USD 618 per cycle), leading to an ICER of USD 6707 per PFLYS for weekly paclitaxel, weekly paclitaxel was cost‐effective in this economic model when using a maximum ICER of USD 100,000 per life‐year saved as a cost‐effective threshold (<a href="./references#CD012007-bbs2-0020" title="DaltonHJ , YuX , HuL , KappDS , BenjaminI , Monk BJ , et al.An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecologic Oncology2012;124(2):199-204.">Dalton 2012</a>). </p> <p>A second cost‐effectiveness analysis performed by Seagle and colleagues similarly described robust cost‐effectiveness for weekly paclitaxel versus tri‐weekly paclitaxel in combination with carboplatin for first‐line treatment of advanced epithelial ovarian cancer when using survival estimates, discontinuation and complication rates from the <a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a> study (<a href="./references#CD012007-bbs2-0057" title="SeagleBL , ShahabiS .Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: an economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic Oncology2017;145(1):9-14.">Seagle 2017</a>). This analysis utilised a three‐state Markov decision model with a 21 day cycle length and 28 month time‐horizon. Costs reported by <a href="./references#CD012007-bbs2-0057" title="SeagleBL , ShahabiS .Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: an economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic Oncology2017;145(1):9-14.">Seagle 2017</a> were updated to the year of equivalence (2021) using readily available on‐line tools (<a href="./references#CD012007-bbs2-0038" title="Inflation Tool 2021. www.inflationtool.com (accessed 9 December 2021).">Inflation Tool 2021</a>). Costs of chemotherapy, complications and surveillance were taken from Medicare or institutional data. Based on this analysis, the ICER for weekly paclitaxel was found to be USD 8714 (95% CI USD 8219 to USD 11016) per PFLYS, and 99.8% of ICER estimates met a more stringent willingness‐to‐pay of USD 50,000 per PFLYS (<a href="./references#CD012007-bbs2-0057" title="SeagleBL , ShahabiS .Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: an economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic Oncology2017;145(1):9-14.">Seagle 2017</a>). </p> </section> </section> <section id="CD012007-sec-0091"> <h3 class="title" id="CD012007-sec-0091">Quality of the evidence</h3> <p>The certainty (quality) of evidence was determined using the tool developed by the GRADE Working Group (<a href="./references#CD012007-bbs2-0031" title="McMaster University (developed by Evidence Prime)GRADEPro GDT.Hamilton (ON): McMaster University (developed by Evidence Prime), accessed prior to 10 January 2021. Available at www.gradepro.org.">GRADEpro GDT</a>). The certainty of evidence was high for OS reported in the main analysis. The certainty of evidence was downgraded by one level to moderate for PFS reported in the main analysis, as absence of blinding may lead to detection bias or performance bias. The certainty of evidence for treatment‐related high‐grade neutropenia was moderate. The lack of blinding was not likely to influence this outcome and sufficient events were reported; however, we downgraded it for severe statistical heterogeneity. The certainty of evidence was high for high‐grade anaemia, as the lack of blinding would not influence this outcome, and a large number of events were reported. The certainty of evidence was low for high‐grade neuropathy, not otherwise specified. We downgraded this by two levels due to imprecision, as well as the absence of blinding which may lead to detection or performance bias. </p> </section> <section id="CD012007-sec-0092"> <h3 class="title" id="CD012007-sec-0092">Potential biases in the review process</h3> <p>Every reasonable effort was made to reduce and to address potential bias by ensuring that all relevant studies were identified, all relevant data could be obtained as far as possible, and that the review process did not introduce further bias. </p> <p>Firstly, we only included RCTs in this review. Furthermore, we conducted searches for all relevant studies, including unpublished studies and studies that were not yet fully‐published. The search strategy also considered studies that were published in a non‐English language. We handsearched all important conference proceedings up to the latest issue. Thus, the likelihood that relevant studies were not identified is thought to be small. During the analysis of this review, we performed all relevant processes in duplicate. Finally, as three authors were leading researchers on one of the included studies (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>), these authors were not involved in decisions regarding inclusion of their study or data extractions. </p> <p>However, this review is limited by the small number of included studies, which precluded the generation of a funnel plot to exclude publication bias. Furthermore, formal IPD were only provided by one out of the four included studies (<a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>) . However, where IPD were not available for the other studies (<a href="./references#CD012007-bbs2-0001" title="ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). In: Oral presentation at the 18th International Meeting of the European Society of Gynecological Oncology. 19 - 22 Oct 2013 Liverpool, United Kingdom of Great Britain and Northern Ireland. ChanJ , BradyM , PensonR , MonkB , BoenteM , WalkerJ , et al.Phase III trial of every-3-weeks paclitaxel vs. Dose dense weekly paclitaxel with carboplatin +/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (nct01167712). International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):9-10. ChanJK , BradyMF , PensonRT , HuangH , BirrerMJ , WalkerJL , et al.Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. New England Journal of Medicine2016;374(8):738-48. ChanJK , BradyMF , PensonRT , MonkBJ , KappDS , BirrerMJ , et al.Neoadjuvant chemotherapy for advanced ovarian, fallopian tube and peritoneal cancer: an ancillary study of GOG 262. Gynecologic Oncology2017;145:68. ">GOG‐0262</a>; <a href="./references#CD012007-bbs2-0003" title="HaranoK , TerauchiF , KatsumataN , TakahashiF , YasudaM , TakakuraS , et al.Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Annals of Oncology2014;25(1):251-7. KatsumataN , YasudaM , IsonishiS , MichimaeH , KimuraE , AokiD , et al.Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: JGOG 3016 trial. Journal of Clinical Oncology2012;30(15):Suppl. KatsumataN , YasudaM , IsonishiS , TakahashiF , MichimaeH , KimuraE , et al.Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncology2013;14(10):1020-6. KatsumataN , YasudaM , TakahashiF , IsonishiS , JoboT , AokiD , et al.Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet2009;374(9698):1331-8. ">JGOG‐3016</a>; <a href="./references#CD012007-bbs2-0004" title="PignataS , ScambiaG , KatsarosD , GalloC , Pujade-LauraineE , De PlacidoS , et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology2014;15(4):396-405. ">MITO‐7</a>), we used the method of <a href="./references#CD012007-bbs2-0034" title="GuyotP , AdesAE , OuwensMJ , WeltonNJ .Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology2012;12(1):9.">Guyot 2012</a> to reconstruct IPD survival time and censoring status. The reconstruction proved to be very accurate. When comparing survival curves obtained from reconstructed survival data for all studies with those obtained after incorporating formal IPD from <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a>, the number‐at‐risk tables were found to be nearly identical, and the compared hazard ratios based on reconstructed survival data were accurate to two or even three decimal places. </p> </section> <section id="CD012007-sec-0093"> <h3 class="title" id="CD012007-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD012007-bbs2-0045" title="MarchettiC , De FeliceF , Di PintoA , D'OriaO , AleksaN , MusellaA , et al.Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Critical Reviews in Oncology/hematology2018;125:30-4.">Marchetti 2018</a> has performed a similar systematic review comparing dose‐dense weekly paclitaxel with standard tri‐weekly paclitaxel in combination with carboplatin for first‐line epithelial ovarian cancer treatment, including the same four studies as our present analysis. However, in the report by <a href="./references#CD012007-bbs2-0045" title="MarchettiC , De FeliceF , Di PintoA , D'OriaO , AleksaN , MusellaA , et al.Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Critical Reviews in Oncology/hematology2018;125:30-4.">Marchetti 2018</a>, no benefit for dose‐dense weekly paclitaxel over standard tri‐weekly paclitaxel was demonstrated. Specifically, there was no significant increase in PFS for women receiving weekly paclitaxel compared to tri‐weekly dosing (HR 0.92, 95% CI 0.81 to 1.04, P = 0.20). Our present meta‐analysis differs from the report by <a href="./references#CD012007-bbs2-0045" title="MarchettiC , De FeliceF , Di PintoA , D'OriaO , AleksaN , MusellaA , et al.Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Critical Reviews in Oncology/hematology2018;125:30-4.">Marchetti 2018</a> due to the incorporation of IPD from the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study. The <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> study was a three‐arm study, whereby two of the three arms utilised weekly paclitaxel combined with carboplatin. In the published data, the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> investigators did not report the HR for weekly paclitaxel (incorporating both weekly paclitaxel groups, i.e. group 2 + group 3) compared to tri‐weekly paclitaxel (group 1). Therefore, in the report by <a href="./references#CD012007-bbs2-0045" title="MarchettiC , De FeliceF , Di PintoA , D'OriaO , AleksaN , MusellaA , et al.Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Critical Reviews in Oncology/hematology2018;125:30-4.">Marchetti 2018</a>, authors approximated the HR for PFS of weekly paclitaxel versus tri‐weekly paclitaxel (HR 1.02, 95% CI 0.94 to 1.10), using summary statistics from the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> publication and methods of <a href="./references#CD012007-bbs2-0066" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR .Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16.">Tierney 2007</a>. As our report has the benefit of IPD from the <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> investigators, we were able to calculate the true HR for PFS of weekly paclitaxel (group 2 + group 3) versus tri‐weekly paclitaxel (group 1), which was 0.94 (95% CI 0.83 to 1.06). This led to a difference in PFS outcome in our report. Furthermore, the report by <a href="./references#CD012007-bbs2-0045" title="MarchettiC , De FeliceF , Di PintoA , D'OriaO , AleksaN , MusellaA , et al.Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Critical Reviews in Oncology/hematology2018;125:30-4.">Marchetti 2018</a> was limited by the lack of fully mature OS data, as well as the lack of QoL data from <a href="./references#CD012007-bbs2-0002" title="BlagdenSP , CookA , PooleC , HowellsL , McNeishIA , DeanA , et al.Quality of life with weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study. International Journal of Gynecological Cancer. Conference: 20th International Meeting of the European Society of Gynaecological Oncology. Austria2017;27(Supplement 4):14. BlagdenSP , CookAD , PooleC , HowellsL , McNeishIA , DeanA , et al.Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncology2020;21(7):969-77. ClampAR , JamesEC , McNeishI , DeanA , Kim J-W, O'DonnellDM , et al.ICON8: overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment. Annals of Oncology Sept 2020;Conference: 45th Congress of European Society for Medical Oncology, ESMO 2020(31 (Suppl 4)). ClampAR , JamesEC , McNeishIA , DeanA , KimJW , O'DonnellDM , et al.Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet2019;394(10214):2084-95. ClampAR , McNeishIA , DeanA , Gallardo-RinconD , KimJW , O'DonnellDM , et al.Response to neoadjuvant chemotherapy in ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. Annals of Oncology2018;Conference: 43rd Congress of European Society for Medical Oncology, ESMO 2018. Germany. 29(Supplement 8):viii336. HookJ , StenningSP , BrentonJ , KayeSB , McNeishIA , NaikR , et al.ICON8: An international randomized trial comparing two dose-dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carboplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology2014;32(15):Suppl. HookJM , FreemanS , StenningSP , McNeishI , PerrenTJ , NaikR , et al.GCIG ICON8 stage IA analysis: safety and feasibility of two dose-fractionated carboplatin-paclitaxel regimens for the first-line treatment of ovarian cancer. International Journal of Gynecological Cancer2013;18th International Meeting of the European Society of Gynaecological Oncology, ESGO, 2013 October 19-22; Liverpool (UK):148-9. JamesEC , HookJ , StenningS , CookA , CoyleC , PetrieJ , et al.ICON8 Stage 1A and 1B analysis: safety and feasibility of weekly carboplatin and paclitaxel regimens in first-line ovarian cancer. Annals of Oncology. Conference: 41st European Society for Medical Oncology Congress, ESMO 2016 October 7-11. Denmark.2016;27:no pagination. MorganRD , McNeishIA , CookAD , JamesEC , LordR , DarkG , et al.Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncology2021;22(2):277-88. ">ICON‐8</a> at the time of publication. In terms of toxicity, the meta‐analysis published by <a href="./references#CD012007-bbs2-0045" title="MarchettiC , De FeliceF , Di PintoA , D'OriaO , AleksaN , MusellaA , et al.Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Critical Reviews in Oncology/hematology2018;125:30-4.">Marchetti 2018</a> agreed with our report on more frequent severe acute anaemia (grade 3 to 4) when paclitaxel is dosed weekly, as well as no difference in terms of high grade neutropenia or febrile neutropenia. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012007-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA Flow Diagram" data-id="CD012007-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA Flow Diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012007-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012007-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-FIG-04" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012007-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-04.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-FIG-04.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-04.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-FIG-05" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD012007-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-05.jpg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-FIG-05.jpg" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-FIG-05.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 1: Progression‐free survival" data-id="CD012007-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 1: Progression‐free survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 2: Progression‐free survival, subgroup analysis by residual disease" data-id="CD012007-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 2: Progression‐free survival, subgroup analysis by residual disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 3: Progression‐free survival, subgroup analysis by FIGO stage" data-id="CD012007-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 3: Progression‐free survival, subgroup analysis by FIGO stage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 4: Progression‐free survival, subgroup analysis by ECOG status" data-id="CD012007-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 4: Progression‐free survival, subgroup analysis by ECOG status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 5: Progression‐free survival, subgroup analysis by bevacizumab receipt" data-id="CD012007-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 5: Progression‐free survival, subgroup analysis by bevacizumab receipt </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 6: Progression‐free survival, subgroup analysis by age distribution" data-id="CD012007-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 6: Progression‐free survival, subgroup analysis by age distribution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 7: Progression‐free survival, subgroup analysis by carboplatin schedule" data-id="CD012007-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 7: Progression‐free survival, subgroup analysis by carboplatin schedule </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 8: Progression‐free survival, subgroup analysis by histotype" data-id="CD012007-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 8: Progression‐free survival, subgroup analysis by histotype </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 9: Overall Survival" data-id="CD012007-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 9: Overall Survival </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 10: Overall survival, subgroup analysis by residual disease" data-id="CD012007-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 10: Overall survival, subgroup analysis by residual disease </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 11: Overall survival, subgroup analysis by FIGO stage" data-id="CD012007-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 11: Overall survival, subgroup analysis by FIGO stage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 12: Overall survival, subgroup analysis by ECOG status" data-id="CD012007-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 12: Overall survival, subgroup analysis by ECOG status </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 13: Overall survival, subgroup analysis by bevacizumab receipt" data-id="CD012007-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 13: Overall survival, subgroup analysis by bevacizumab receipt </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 14: Overall survival, subgroup analysis by age distribution" data-id="CD012007-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 14: Overall survival, subgroup analysis by age distribution </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 15: Overall survival, subgroup analysis by carboplatin schedule in dose‐dense arm" data-id="CD012007-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 15: Overall survival, subgroup analysis by carboplatin schedule in dose‐dense arm </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 16: Overall survival, subgroup analysis by histotype" data-id="CD012007-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 16: Overall survival, subgroup analysis by histotype </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 17: Grade 3 or 4 neutropenia" data-id="CD012007-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 17: Grade 3 or 4 neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 18: Febrile neutropenia" data-id="CD012007-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 18: Febrile neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 19: Grade 3 or 4 anaemia" data-id="CD012007-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 19: Grade 3 or 4 anaemia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 20: Grade 3 or 4 leucopenia" data-id="CD012007-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 20: Grade 3 or 4 leucopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 21: Grade 3 or 4 thrombocytopenia" data-id="CD012007-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 21: Grade 3 or 4 thrombocytopenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 22: Grade 3 or 4 transaminitis" data-id="CD012007-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 22: Grade 3 or 4 transaminitis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 23: Grade 3 or 4 fatigue" data-id="CD012007-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 23: Grade 3 or 4 fatigue </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 24: Grade 3 or 4 myalgia" data-id="CD012007-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 24: Grade 3 or 4 myalgia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 25: Grade 3 or 4 arthralgia" data-id="CD012007-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 25: Grade 3 or 4 arthralgia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 26: Grade 3 or 4 anorexia" data-id="CD012007-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 26: Grade 3 or 4 anorexia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 27: Grade 3 or 4 diarrhoea" data-id="CD012007-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 27: Grade 3 or 4 diarrhoea </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 28: Grade 3 or 4 vomiting" data-id="CD012007-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 28: Grade 3 or 4 vomiting </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 29: Grade ≥ 2 neuropathy" data-id="CD012007-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 29: Grade ≥ 2 neuropathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 30: Grade 3 or 4 neuropathy" data-id="CD012007-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 30: Grade 3 or 4 neuropathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 31: Any‐grade alopecia" data-id="CD012007-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 31: Any‐grade alopecia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 32: Any‐grade mucositis" data-id="CD012007-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 32: Any‐grade mucositis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 33: Grade 3 or 4 hypersensitivity" data-id="CD012007-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 33: Grade 3 or 4 hypersensitivity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 34: Treatment discontinuation" data-id="CD012007-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 34: Treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012007-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/urn:x-wiley:14651858:media:CD012007:CD012007-CMP-001.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 35: Dose modification" data-id="CD012007-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_t/tCD012007-CMP-001.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1: Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment, Outcome 35: Dose modification </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/media/CDSR/CD012007/image_n/nCD012007-CMP-001.35.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012007-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Weekly paclitaxel plus carboplatin compared to Three‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> first‐line treatment of ovarian cancer<br/><b>Setting:</b> Hospital<br/><b>Intervention:</b> Weekly paclitaxel plus carboplatin<br/><b>Comparison:</b> Three‐weekly paclitaxel plus carboplatin </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with tri‐weekly paclitaxel plus carboplatin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Weekly paclitaxel plus carboplatin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression‐free survival (PFS)<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.89<br/>(0.81 to 0.98) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3699<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin likely improves progression‐free survival slightly.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>177 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>159 per 1000<br/>(146 to 173) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Overall survival (OS)<br/>follow‐up: range 22.3 months to 76.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.92<br/>(0.79 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3699<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin results in little to no difference in overall survival.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/>(53 to 71) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological adverse event: Grade 3/4 neutropenia<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.11<br/>(0.86 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3639<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin likely results in little to no difference in Grade 3/4 neutropenia. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>534 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>593 per 1000<br/>(459 to 764) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Haematological adverse event: Grade 3/4 anaemia<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.57<br/>(1.12 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3639<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin increases Grade 3/4 anaemia .</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>158 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>249 per 1000<br/>(177 to 349) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Neurological adverse event: Grade 3/4 neuropathy, not otherwise specified<br/>follow‐up: range 22.3 months to 36.8 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.12<br/>(0.64 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3639<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weekly paclitaxel plus carboplatin may result in little to no difference in Grade 3/4 neuropathy. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/>(26 to 78) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RR:</b> risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to risk of bias (detection bias as patients and investigators were not blinded). </p> <p><sup>2</sup> Downgraded one level for severe statistical heterogeneity. </p> <p><sup>3</sup> Downgraded one level due to imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment of ovarian cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/full#CD012007-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012007-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.81, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Progression‐free survival, subgroup analysis by residual disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Absent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.70, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 ≤ 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.63, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 &gt; 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 No surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.70, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Progression‐free survival, subgroup analysis by FIGO stage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Stage I or II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.66, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Stage I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [0.23, 16.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Stage II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.55, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.5 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.6 Stage III or IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Progression‐free survival, subgroup analysis by ECOG status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 ECOG 0 or 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 ECOG 2, 3, or 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 ECOG 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 ECOG 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.86, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 ECOG 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.60, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Progression‐free survival, subgroup analysis by bevacizumab receipt <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 No bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.66, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 Received bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.83, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Progression‐free survival, subgroup analysis by age distribution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 &lt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.71, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 &gt;/= 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.70, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 &lt; 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 &gt;/= 70 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.61, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Progression‐free survival, subgroup analysis by carboplatin schedule <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 Tri‐weekly carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 Weekly carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.93, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Progression‐free survival, subgroup analysis by histotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Serous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Non‐serous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.78, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Overall Survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.79, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Overall survival, subgroup analysis by residual disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 Absent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 ≤ 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.49, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 &gt; 1 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 No surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Overall survival, subgroup analysis by FIGO stage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 Stage I or II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.46, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 Stage I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.17, 9.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 Stage II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.41, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 Stage III</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.5 Stage IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Overall survival, subgroup analysis by ECOG status <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 ECOG 0 or 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.74, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 ECOG 2, 3 or 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.59, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Overall survival, subgroup analysis by bevacizumab receipt <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 No bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.76, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 Mixed population of participants who did/did not receive bevacizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.72, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Overall survival, subgroup analysis by age distribution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 &lt; 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.56, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 &gt;/= 60 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.61, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Overall survival, subgroup analysis by carboplatin schedule in dose‐dense arm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 Weekly carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.75, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 Tri‐weekly carboplatin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.76, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Overall survival, subgroup analysis by histotype <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 Serous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 Non‐serous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Grade 3 or 4 neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.86, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Febrile neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.56, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Grade 3 or 4 anaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.12, 2.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Grade 3 or 4 leucopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.29, 9.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.21 Grade 3 or 4 thrombocytopenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.61, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.22 Grade 3 or 4 transaminitis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.48, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.23 Grade 3 or 4 fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.76, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.24 Grade 3 or 4 myalgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.04, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.25 Grade 3 or 4 arthralgia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.07, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.26 Grade 3 or 4 anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.13, 5.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.27 Grade 3 or 4 diarrhoea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.77, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.28 Grade 3 or 4 vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.62, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.29 Grade ≥ 2 neuropathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.1 Not otherwise specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.43, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.2 Sensory neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.64, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.29.3 Motor neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.69, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.30 Grade 3 or 4 neuropathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.1 Not otherwise specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.64, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.2 Sensory neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.79, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.30.3 Motor neuropathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.67, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.31 Any‐grade alopecia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.65, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.32 Any‐grade mucositis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [0.37, 34.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.33 Grade 3 or 4 hypersensitivity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.44, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.34 Treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.42, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.35 Dose modification <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.1 Dose delay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [1.21, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.2 Dose reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.38, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.35.3 Dose omission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [2.40, 3.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Weekly paclitaxel plus carboplatin compared to tri‐weekly paclitaxel plus carboplatin for first‐line treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012007.pub2/references#CD012007-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012007.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012007-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012007-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012007-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012007-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012007-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012007-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD012007-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012007-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012007-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012007\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012007\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012007\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012007\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012007\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012007.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012007.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012007.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012007.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012007.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725041061"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012007.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725041065"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012007.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e718ade041bdf',t:'MTc0MDcyNTA0MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 